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 ABSTRACT 
Dihydroxyacetone phosphate (DHAP)-dependent aldolases have been intensively studied 
and widely used in the synthesis of carbohydrates and complex polyhydroxylated molecules. 
However, the strict specificity toward donor substrate DHAP greatly hampers their synthetic 
utility. We transformed DHAP dependent aldolases mediated in vitro reactions into 
bioengineered Escherichia coli (E. coli). Such flask-to-cell transformation addressed several key 
issues plaguing in vitro enzymatic synthesis: 1) it solves the problem of DHAP availability by in 
vivo hijacking DHAP from glycolysis pathway of bacterial system, 2) it circumvents purification 
of recombinant aldolases and phosphatase, and 3) it dephosphorylates resultant aldol adducts in 
vivo, thus eliminating the additional step for phosphate removal and achieving in vivo phosphate 
recycling. The engineered E. coli strains tolerate a wide variety of aldehydes as acceptor, and 
provide a set of biologically relevant polyhydroxylated molecules in gram scale.  
Sialic acids exist in abundance in glycan chains of glycoproteins and glycolipids on the 
surface of all eukaryotic cells and some prokaryotic cells. Their presence affects the molecular 
properties and structure of glycoconjugates, modifies their functions and interactions with other 
molecules. The sialylation status, referring to the expression levels and linkages of sialic acids on 
the cell surface, is determined by the dynamic balance between sialylation and desialylation 
(removal of sialic acids). Sialylation is mainly regulated through expression and activity of 
sialyltransferases. And the mainstream idea attributes desialylation to the sialidases. However, 
more and more emerging evidences support the existence of ROS/RNS mediated chemical 
desialylation process under some pathological conditions. We used electrochemical oxidation of 
sialic acid conjugates to mimic ROS mediated chemical desialylation. Such electrochemical 
desialylation mimicry reveals that 1) β-linked sialic acid is much more difficult to de desialylated 
than α-linked sialic acid, 2) electron withdrawing residue and bulky underlying residue can 
facilitate the desialylation, 3) α-2,3-linked sialic acid is easier to be desialylated than α-2,6- and 
α-2,8-linked sialic acid. This information is highly valuable for identifying the ROS species 
participated in ROS mediated desialylation and unveiling corresponding mechanisms. The 
mechanism of ROS mediated desialylation was proposed to go through radical decarboxylation. 
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1. CHAPTER 1 DIHYDROXYACETONE PHOSPHATE (DHAP)-DEPENDENT 
ALDOLASES: FROM FLASK REACTION TO CELL-BASED SYNTHESIS 
 
 
1.1 Introduction 
Aldolase (EC 4.1.2.x) is a subclass of lyase, which catalyzes the reversible addition of a 
ketone donor (nucleophile) onto an aldehyde acceptor (electrophile). While most aldolases are 
specific for their donors, they often tolerate different aldehydes as acceptors. Due to excellent 
control over stereochemistry and mild reaction conditions, aldolases exhibit unrivaled efficiency 
in the synthesis of carbohydrates and complex polyhydroxylated molecules, which are difficult 
to prepare and handle by conventional chemical synthesis. One elegant paradigm is the synthesis 
of statin (cholesterol-lowering drugs) side chain by deoxyribose-5-phosphate aldolase (DERA) 
catalyzed cascade aldol/aldol/hemiacetalization reaction between one molecule of α-substituted 
acetaldehyde and two molecules of acetaldehyde.1, 2 For the high efficiency and excellent 
stereoselectivity, this method was developed into the industrial scale production of statin side 
chain and Pfizer developed the world top-selling drug Lipitor (atorvastatin)3-7 with over $125 
billion total sales since its approval in 1996. Among known aldolases, DHAP-dependent 
aldolases are most intensively studied and widely used so far, as configurations of two newly 
generated stereogenic centers can be chosen and controlled by an appropriate choice of four 
known DHAP-dependent aldolases.8, 9 DHAP-dependent aldolases are comprised of Fructose-
1,6-bisphosphate aldolase (FruA), Fuculose-1-phosphate aldolase (FucA), Tagatose-1,6-
2 
bisphosphate aldolase (TagA) and Rhamnulose-1-phosphate aldolase (RhuA), which catalyze the 
reversible aldol addition reaction of DHAP to aldehyde acceptors. These four DHAP-dependent 
aldolases are stereocomplementary, thus a complete set of four stereoisomers could be accessed 
(Scheme 1.1). 
 
 
Scheme 1.1 Stereochemical complementarity of DHAP-dependent aldolases. 
 
1.2 Synthetic Applications of DHAP Dependent Aldolases 
With respect to synthetic application of DHAP-dependent aldolases, over 200 research 
papers have been published, ranging from synthesis of monosaccharides,10-12 iminocyclitols,13-16 
higher carbon sugars,17, 18 carbocycles19-22 and natural products23-25 to active pharmaceutical 
intermediates26-28 (Scheme 1.2). More than 100 aldehydes have been used as acceptors for 
DHAP-dependent aldolases. These aldehydes can be unhindered aliphatic and aromatic 
aldehydes, α-heteroatom substituted aldehydes, azido aldehydes, protected amino aldehydes, 
monosaccharides, and their derivatives. The use of multienzyme systems and engineering of 
DHAP-dependent aldolases further broaden the substrate scope of aldehyde acceptors to 
unprecedented α, β-unsaturated aldehydes29 and complex synthetic aldehydes.30 Recent work on 
3 
combining DHAP-dependent aldolases mediated aldol reactions with other enzymatic 
transformations allows rapid construction of complex molecules with multiple stereogenic 
centers and diverse functionalities.31 32-34 
 
 
Scheme 1.2 Synthetic applications of DHAP-dependent aldolases. 
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1.3 DHAP Generation 
However, the strict specificity toward donor substrate DHAP greatly hampers the large 
scale synthetic utility of DHAP-dependent aldolases, due to high cost and lability of DHAP.32, 35 
Therefore, effective production of DHAP is instrumental, and several chemical and enzymatic 
approaches have been developed for its synthesis. Chemical approaches focus on producing 
storable precursors that can be easily converted to DHAP immediately before its use (Scheme 
1.3).36-44 However, they suffer from either low yields, complicated work-up, or toxic reagents or 
catalysts.45  
 
 
Scheme 1.3 Chemical routes to DHAP. 
 
Enzymatic approaches generate DHAP in situ and follow three general routes: 
phosphorylation of dihydroxyacetone (DHA) (Scheme 1.4 I),29, 46-50 oxidation of L-glycerol 3-
phosphate (L-GP) (Scheme 1.4 II),51-55 and mimicking glycolysis (Scheme 1.4 III).36, 56 Though 
enzymatic approaches start from cheap non-phosphorylated precursors (DHA, glycerol, sucrose), 
5 
they employ multiple costly isolated enzymes. Both chemical and enzymatic approaches require 
further improvement to serve as a basis for scalable and cost-effective production of DHAP. 
Another issue associated with large scale synthetic utility of DHAP-dependent aldolases is that 
an additional step is required to remove phosphate group of aldol adducts, which necessitates the 
use of phosphatase and thus causes non-productive waste of phosphate component. 
 
 
Scheme 1.4 Enzymatic routes to DHAP. 
 
1.4 Overcoming DHAP Dependence 
A desirable solution is to eliminate the requirement of DHAP and use readily available, 
inexpensive DHA. Recent efforts in overcoming DHAP-dependence by substrate/reaction 
6 
engineering, exploitation of newly discovered or designed enzymes, and directed evolution of 
aldolases have achieved great success. 
 
1.4.1 Substrate/reaction engineering 
Arsenate, vanadate, and borate can form esters with Dihydroxyacetone (DHA) in situ and 
reversibly. These esters act as phosphate ester (DHAP) mimics and can be accepted as donor by 
some DHAP-dependent aldolases (Scheme 1.5). Therefore, with the presence of these inorganic 
anions, DHAP-dependent aldolases can accept DHA as donor. In the presence of arsenate, FruA, 
FucA and RhuA can accept DHA as donor,57, 58 but the required high concentration and the high 
toxicity of arsenate make this approach unsuitable to be used in preparative applications. For 
vanadate and borate, only RhuA can accept DHA as donor.59-61 However, vanadate is susceptible 
of participating in secondary redox reactions and its expense limits its practical utility. 
 
 
Scheme 1.5 DHAP-dependent aldolases accept DHA as donor in the presence of arsenate, 
vanadate or borate. 
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1.4.2 Discovery and design of new enzymes 
Fructose 6-phosphate aldolase (FSA) from E. coli, the first example of enzymes using 
dihydroxyacetone (DHA) as donor substrate, is one of major discoveries in this field (Scheme 
1.6).62 Besides DHA, FSA also can accept hydroxyacetone (HA), hydroxybutanone (HB) and 
even glycolaldehyde (GA) as donor substrates.35, 63-65 This broad donor substrate specificity is 
remarkable, especially the acceptance of GA as an donor substrate, which offers the 
unprecedented opportunity of enzymatic cross-aldol addition reactions of glycolaldehyde to 
aldehydes, thereby opening new promising biocatalytic strategies for the immediate and 
stereoselective synthesis of aldoses (instead of ketoses derived from usual ketone donors) and 
related complex analogs or derivatives. Structurally related transaldolase B variants (TalB-
F178Y and TalB-F178Y/R181E) of E. coli are designed aldolases and also can accept DHA, HA 
and HB as donor substrates.66 FSA, TalB-F178Y and TalB-F178Y/R181E give aldol products 
with (3S,4R)-configuration and can be considered as an alternative to FruA.  
 
 
Scheme 1.6 FSA, TalB-F178Y and TalB-F178Y/R181E mediated aldol reactions. 
 
Recently, a bifunctional aldolase/kinase enzyme (FruA-DHAK-FruA) was constructed by 
gene fusion, which consists of a monomeric FruA and a homodimeric DHAK (Scheme 1.7).67 
The fusion protein retains both kinase and aldolase activity and has been applied for the 
8 
stereoselective C-C bond formation starting from DHA as the initial donor and an aldehyde with 
20-fold increase in the reaction rate compared to the multi-enzyme system of the free parent 
enzymes. However, a phosphatase is still needed to remove phosphate group from aldol adducts. 
 
 
Scheme 1.7 Application of FruA-DHAK-FruA to stereoselective C-C bond formation. 
 
1.4.3 Directed evolution of enzymes 
A directed evolution approach was successfully applied to engineer RhuA to avoid the 
use of DHAP (Scheme 1.8). Thus, after random mutagenesis and a proper selection system, 
RhuA-N29D was able to accept DHA as a donor and furnish aldol adducts with (3R,4S) 
configuration.68 Thus, RhuA-N29D is stereocomplementary to FSA, TalB-F178Y and TalB-
F178Y/R181E. However, the acceptor scope of RhuA-N29D catalyzed aldol addition of DHA to 
aldehyde still hasn’t been fully explored. 
 
 
Scheme 1.8 RhuA-N29D mediated aldol addition of DHA to aldehydes. 
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In summary, these DHAP independent methods only can provides (3S, 4R) and (3R, 4S) 
configuration products. Access to (3R, 4R) and (3S, 4S) products still has to use DHAP as donor. 
And none of these methods has ever been realized on more than lab scale. 
 
1.5 In vitro one-pot four-enzyme synthesis of ketoses with FruA 
In glycolysis, FruA catalyzes the reversible degradation of D-fructose 1,6-bisphosphate to 
D-glyceraldehyde 3-phosphate (GAP) and DHAP. However, the equilibrium constant for this 
reaction strongly favors the synthesis direction, which makes FruA synthetically useful as a 
biocatalyst.69 FruA from rabbit muscle (RAMA) is widely used, due to its commercial 
availability, high activity, and relaxed aldehyde substrate specificity.36, 70, 71 Unfortunately, 
RAMA suffered from low operational stability and loss of activity during synthesis.72 In contrast, 
FruA from bacterial sources, such as FruA from Staphylococcus carnosus (FruAS.car), is 
exceptionally temperature and pH stable.72, 73  
We developed a one-pot four-enzyme approach for the synthesis of rare sugars using 
FruAS.car (Table 1.1). In this one-pot reaction sequence, DHAP was firstly generated from the 
oxidation of L-GP by glycerol phosphate oxidase (GPO).51, 74 The by-product of this oxidation, 
H2O2, which shows toxicity to GPO, was thus selectively degraded by catalase. The DHAP 
generated in situ was then coupled with aldehyde by aldolase to give the sugar-1-phosphate, 
which not only prevents product inhibition of GPO by DHAP and thus promotes the conversion 
of L-GP, but also suppresses any decomposition of the labile DHAP since it does not accumulate 
in the reaction mixture.51 Lastly, the phosphate group was removed under acidic conditions by 
acid phosphatase (AP) to provide sugars in a one-pot fashion. As summarized in Table 1.1, 
FruAS.car accepted D- and L-glyceraldehydes, and various aliphatic aldehydes as acceptors, and 
10 
demonstrated excellent stereoselectivity. Only one diastereomer with (3S, 4R) configuration was 
isolated for each reaction. 
This one-pot four-enzyme approach generates DHAP in situ from cheap DL-GP, which 
can reduce the synthetic cost, and provides a straight forward method for the synthesis of 
ketoses. However, the usage of four isolated enzymes is the major issue. 
Table 1.1 One-pot four-enzyme synthesis of ketoses with FruA 
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1.6 Transforming DHAP-dependent Aldolases Mediated Reactions from Flask into Cell-
Based Synthesis 
Synthetic biology, a recently emerging discipline which utilizes elaborate bio-engineered 
organisms as “programmable synthetic machinery” to execute transformations inside cells, has 
completely revolutionized the notion of the conventional enzymatic synthesis into an era of 
advanced manufacturing of chemicals in a highly efficient and sustainable fashion.75-77 Advances 
in DNA technologies and bioinformatics enable the reconstruction and perfection of such genetic 
devices. Thus, synthetic biology could provide appealing opportunities and solutions to issues 
blocking large scale synthetic applications of DHAP-dependent aldolases by technically 
manipulating microbial hosts to execute the aldolase-catalyzed reactions inside cells and afford 
desired products. 
DHAP is a metabolite in the universal glycolytic pathway. In glycolysis, glucose is 
metabolized into fructose 1,6-bisphosphate via three enzymatic steps, which is then split by FruA 
into two inter-convertible triose phosphates, DHAP and GAP.78 The concentration ratio of 
DHAP to GAP is 96 % to 4 % due to favored formation of DHAP by TIM.79 By introducing and 
overexpressing an aldolase and a phosphatase genes in E. coli cells, a “side way” or “external 
biosynthetic pathway” can be set up to hijack DHAP from the glycolytic pathway and couple it 
with an externally added aldehyde to provide phosphorylated aldol adduct. The formed aldol 
adduct will then be dephosphorylated by an overexpressed phosphatase and secreted out to the 
fermentation media to give desired product (Scheme. 1.9). 
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Scheme 1.9 Hijacking DHAP from the glycolytic pathway. 
 
To fulfill such transformation (Figure 1.1), three major issues need to be addressed. First, 
a suitable aldolase gene must be introduced and overexpressed in the host cell. The expressed 
aldolase would couple glycolysis pathway with aldol reaction to afford phosphorylated aldol 
adducts. Second, an appropriate phosphatase gene needs to be introduced and overexpressed. 
High intracellular accumulation of phosphorylated aldol adducts is expected to be toxic or, at 
least, a burden to cells. The phosphatase should be able to selectively dephosphorylate resultant 
aldol adducts under physiological conditions but without any interference to other 
phosphorylated metabolic intermediates, which may have a negative influence on the whole 
engineered system. After dephosphorylation, final product would be secreted out of host cells. 
This will shift glycolysis and aldol reaction towards product formation and make purification of 
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final product much easier. Additionally, the removed phosphate could be recycled inside cells. 
Third, bacteria growth and product synthesis must be well balanced. Hijacking DHAP from 
glycolysis will greatly reduce energy production, disrupt redox balance, and reduce growth in 
host cells. A suitable condition must be explored to maximize production while maintain bacteria 
growth. 
 
 
Figure 1.1 Green and sustainable E. coli synthetic machinery. 
 
1.6.1 Validation of the E. coli synthetic machinery design 
We are very interested in FruA, one class of DHAP-dependent aldolase, owing to its high 
stereoselectivity and relaxed aldehyde substrate specificity. FruA from Staphylococcus carnosus 
(FruAS.car) encoded by gene fda displays unusual stability across a wide range of temperature and 
pH conditions while remains quite relaxed acceptor specificity.72, 73 At the same time, FruAS.car 
has been demonstrated to exhibit high stereoselectivity in aldol reactions, selectively furnishing 
aldol products with (3S,4R)-threo configuration.55, 72 Thus, we chose FruAS.car as aldolase. YqaB 
from E. coli (YqaBE.coli) encoded by gene yqaB could dephosphorylate D-fructose-1-phosphate 
but shows no activity towards aldose phosphates, ketose terminal phosphates or other 
phosphorylated metabolic intermediates.80 Our in vitro study also showed that YqaBE.coli could 
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dephosphorylate D-sorbose-1-phosphate, D-psicose-1-phosphate, L-tagatose-1-phosphate, L-
fructose-1-phosphate but showed almost no activity toward DHAP under neutral conditions. 
Therefore, we chose YqaBE.coli as phosphatase. Meanwhile, we chose 3-trifluoroacetamido 
propanal 1 as model aldehyde acceptor owing to its excellent solubility in water. 
To construct recombinant E. coli strain, fda and yqaB genes were cloned into pCDFDuet-
1 (Novagen), a vector which allows high-level expression of two proteins under induction of 
isopropyl β-D-1-thiogalactopyranoside (IPTG). The resulted plasmid pCDF-fda-Y was 
transformed into E. coli BL21Star (DE3) to provide recombinant E.coli strain FruA-Y, which 
was grown aerobically at 37 oC, 220 rpm in LB broth medium until OD600 value reached 1.0. 
Then temperature was switched to 30 oC and IPTG was added to induce co-expression of FruA 
and YqaB for 12 h. Subsequently, 1 and glucose were fed. To our delight, after purification, 234 
mg 2 was provided with 11.3 % yield. 
 
1.6.2 Optimization of fermentation conditions for maximum product synthesis 
After validation of such transformation, we set out to optimize fermentation conditions 
by using 1 as model acceptor. Several key parameters critical to fermentation yield were 
investigated (Table 1.2). Glucose is energy source and carbon source of living cell system, while 
high concentration of glucose will lead to catabolite repression. In order to determine the optimal 
initial glucose concentration in medium, a variety of glucose concentrations, ranging from 2 g/L 
to 12 g/L, were examined (entries 1-6). After glucose concentration is over 4 g/L threshold, yield 
of 2 would not increase anymore and keep almost constant until it reached 12 g/L, at which point 
yield of 2 began to decrease. Therefore, initial glucose concentration was chosen to be 4 g/L. 
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Notably, if glucose was fed during cell proliferation phase or induction stage, yield of 2 would 
decrease dramatically. 
Addition of IPTG would affect growth of cells and expression of target genes. Therefore, 
IPTG was added at different levels of cell density, determined by corresponding OD600 value, to 
investigate effect of IPTG addition time point on fermentation yield.  After 12 h induction, OD600 
value of all cell cultures reached around 2.3. As illustrated in entries 2, 7-11, yield of 2 increased 
almost in a linear relationship with the increase of cell OD600 values until OD600 equaled to 1.8, 
at which point yield of 2 reached a plateau at 41.7 %. Thus, the optimum time point of IPTG 
addition is the time at which OD600 value is equal to or larger than 1.8. 
LB Broth medium is a nutritionally rich medium and supplies essential growth factors 
that E. coli would otherwise have to synthesize. While ECAM (see recipe in supporting 
information) is a mineral salt medium and provides all kinds of metals and essential trace 
elements for E. coli. Thus, in order to probe effect of cultural medium on output of the E. coli 
strain, LB Broth and ECAM media were examined, as well as their combinations. As 
demonstrated in Table 1.1 entries 11-15, LB Broth turned out to be far superior to ECAM with 
respect to yield of 2 (entry 11 vs. 15). However, an appropriate combination of these two media 
can increase yield of 2.  When these two media were mixed in a 3:1 volumetric ratio, yield of 2 
was increased from 41.7 % to 49.8 % (entry 11 vs. entry 12). Yield of 2 was further increased to 
50.0 % by mixing LB Broth and ECAM in a 1:1 volumetric ratio (entry 13). Further increase of 
ECAM ratio led to decrease of production yield (entry 14). Therefore, the optimal medium is 
combination of LB Broth and ECAM in a 1:1 volumetric ratio. In addition, when E. coli strain 
BL21Star (DE3) was used to perform fermentation under optimized conditions, no product was 
detected (entry 16), which indicated that the background reactions were negligible. 
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Table 1.2 Condition Optimization for maximum production. 
 
Entrya Medium Glucose  (g/L)b 
Cell densityc 
OD600 
Incubation 
time   (h) Yield
d 
1 LB Broth 2 1.0 12 19.7 % 
2 LB Broth 4 1.0 12 27.6 % 
3 LB Broth 6 1.0 12 27.5 % 
4 LB Broth 8 1.0 12 27.6 % 
5 LB Broth 10 1.0 12 27.4 % 
6 LB Broth 12 1.0 12 15.4 % 
7 LB Broth 4 1.2 11 30.1 % 
8 LB Broth 4 1.4 10 33.5 % 
9 LB Broth 4 1.6 9 36.7 % 
10 LB Broth 4 1.8 8 41.7 % 
11 LB Broth 4 1.95 8 41.7 % 
12 LB Broth/ECAM (3/1, v/v) 4 > 1.8 8 49.8 % 
13 LB Broth/ECAM (1/1, v/v) 4 > 1.8 8 50.0 % 
14 LB Broth/ECAM (1/3, v/v) 4 > 1.8 8 40.4 % 
15 ECAM 4 > 1.8 11 28.5 % 
16e LB Broth/ECAM (1/1, v/v) 4 > 1.8 8 0 % 
 
a Fermentation conditions: strain FruA-Y  was grown aerobically at 37 oC, 220 rpm in 200 mL 
medium until OD600 reached certain value. Then temperature was switched to 30 oC and IPTG 
was added to induce co-expression of FruA and YqaB for 12 h. Subsequently, 8 mmol 1 and 
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glucose were fed. b Initial glucose concentration in medium. c At this cell density, IPTG was 
added.  d HPLC yield based on acceptor 1. e E. coli strain BL21Star (DE3) was used. 
 
1.6.3 Production of polyhydroxylated molecules via E. coli FruA-Y strain 
After identified optimal fermentation conditions, we set out to investigate the scope and 
limitations of such FruA-Y E. coli synthetic factory by using a variety of cell membrane 
permeable aldehydes as acceptors. FruA-Y strain demonstrated superb promiscuity towards 
different aldehyde acceptors. As indicated in Table 1.3, a set of small aldehydes were taken up 
by FruA-Y E. coli cells and subjected to aldol reaction with glycolytic intermediate DHAP, 
followed by in situ dephosphorylation， to yield desired aldol products. When 1 was used as 
acceptor, 2.47 g 2 was provided with 23.8 % yield as a single stereoisomer (dr > 95:5). However, 
concentration of 2 in fermentation medium was 5.18 g/L (determined by HPLC) and 
corresponding yield was 50.0 % (entry 1). The low isolated yield is mainly attributed to loss of 
product during purification. Along the same line, 3-trichloroacetamido propanal gave 4.41 g 
(3S,4R)-6-trichloroacetamido-1,3,4-trihydroxyhexan-2-one with 35.7 % yield and 92:8 dr (entry 
2); 3-Difluoroacetamido propanal gave 2.26 g (3S,4R)-6-difluoroacetamido-1,3,4-
trihydroxyhexan-2-one with 23.4 % yield and 92:8 dr (entry 3); 3-(methylthio)propanal gave 327 
mg (3S,4R)-1,3,4-trihydroxy-6-(methylthio)hexan-2-one with 2.8 % yield and 92:8 dr (entry 4); 
4,4,4-trifluorobutanal gave 716 mg (3S,4R)-7,7,7-trifluoro-1,3,4-trihydroxyheptan-2-one with 4.7 
% yield and 87:13 dr (entry 5). Low fermentation yields of 3-(methylthio)propanal and 4,4,4-
trifluorobutanal are mainly due to vaporization of aldehyde acceptors during incubation and their 
poor cell membrane permeability. When D-glyceraldehyde was used as acceptor, 947 mg of D-
fructose was afforded with 26.3 % yield. However, HPLC yield before purification was 65.6 % 
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(entry 6). In addition, when (R)-3-trifluoroacetamido-2-hydroxypropanal and (S)-3-
trifluoroacetamido-2-hydroxypropanal were used as acceptors, 827 mg 3 and 513 mg 4 were 
afforded respectively (entries 7-8). 
 
Table 1.3 Production of polyhydroxylated molecules via E. coli strain FruA-Y. 
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a Fermentation conditions: strain FruA-Y  was grown aerobically at 37 oC, 220 rpm in 1 L LB 
Broth/ECAM (1/1, v/v) medium until OD600 reached 1.8-2.0. Then temperature was switched to 
30 oC and IPTG was added to induce co-expression of FruA and YqaB for 12 h. Subsequently, 
aldehyde acceptor and glucose were fed. b Determined by 1H NMR. c HPLC yield based on 
aldehyde acceptor. d 60 mmol aldehyde was used. e 70 mmol aldehyde was used. f 1 L ECAM 
was used as medium and 20 mmol aldehyde was used. g Determined by HPLC. h 27.3 mmol 
aldehyde was used. ND, not determined. 
 
1.6.4 Synthesis of D-fagomine, 1-Deoxymannojirimycin (DMJ), 1-Deoxynojirimycin (DNJ) 
D-fagomine, 1-Deoxymannojirimycin (DMJ), 1-Deoxynojirimycin (DNJ) and their 
derivatives are effective inhibitors of glycosidases and glycosyltransferases, and exert profound 
effect on N-linked glycoprotein processing and maturation, as well as cell-cell and cell-virus 
recognition.81 Therefore, they have gained considerable clinical importance in the treatment of 
cancer, type II diabetes, viral diseases such as HIV, hepatitis B and C, Gaucher’s disease, and 
other glycosphingolipid storage disorders.82-85 For example, D-fagomine can effectively reduce 
blood glucose peak when taken together with sucrose or starch, without stimulating insulin 
release, and help to eliminate the excess of enterobacteria and lower weight gain by selectively 
agglutinating fimbriated enterobacteria and inhibiting their adhesion to the intestinal mucosa.86, 87 
Miglitol, N-hydroxyethyl DNJ, is currently used as potent second-generation digestive α-
glucosidase inhibitor for treatment of type II diabetes; Miglustat, N-butyl DNJ, is currently used 
for treatment of Type 1 Gaucher disease (GD1) and Niemann-Pick type C (NPC) disease.88-90 By 
simple deprotection and reductive amination, product 2, 3 and 4 were transformed to D-
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fagomine, DMJ and DNJ respectively with high yields and no other diastereomers were detected 
by 1H NMR analysis (Scheme 1.10). 
 
 
Scheme 1.10 Synthesis of D-fagomine, DMJ and DNJ. 
 
1.6.5 Production of polyhydroxylated molecules via E. coli FucA-Y and RhaD-Y strains 
To further expand applications of such E. coli synthetic machinery, recombinant E. coli 
strains FucA-Y and RhaD-Y were constructed following the same procotol of FruA-Y with fucA 
gene encoding L-fuculose-1-phosphate aldolase (FucA) from Thermus. thermophilus HB8 and 
rhaD gene encoding L- rhamnulose-1-phosphate aldolase (RhaD) from E. coli.  For FucA-Y 
strain, D-glyceraldehyde gave 960 mg D-psicose with 35.6 % yield and 92:8 dr (Table 1.4, entry 
1); 1 gave 665 mg (3R,4R)-6-trifluoroacetamido-1,3,4-trihydroxy-hexan-2-one 5 with 12.8 % 
yield and 87:13 dr (Table 1.4, entry 2). For RhaD-Y strain, D-glyceraldehyde provided 281 mg 
D-piscose and 286 mg D-sorbose with 10.4 % and 10.6 % yield respectively (Table 1.4, entry 3); 
1 yielded 1.16 g (3R,4S)-6-trifluoroacetamido-1,3,4-trihydroxy-hexan-2-one 6 with 22.4 % yield 
and 89:11 dr (Table 1.4, entry 4). The successful application of D-glyceraldehyde and 1 in 
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strains FucA-Y and RhaD-Y indicated that many other aldehydes also could be applied in these 
two E. coli strains. 
 
Table 1.4 Production of polyhydroxylated molecules via E. coli strains FucA-Y and RhuA-Y. 
 
a Fermentation conditions: same as Table 2. b 1 L ECAM was used as medium and 15 mmol 
aldehyde was used c 1 L LB Broth/ECAM (1/1, v/v) was used as medium and 20 mmol aldehyde 
was used. d Determined by HPLC. e Determined by 1H NMR. 
 
1.6.6 Comparing the in vivo and in vitro stereoselectivities of FruA, FucA, and RhuA  
To compare the in vivo and in vitro stereoselectivities of FruA, FucA and RhuA, 2, 5, and 
6 were synthesize via in vitro one-pot four-enzyme system (Table 1.5). GPO catalyzed the in 
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situ generation of DHAP from DL-glycerol 3-phosphate. Then, aldolases coupled DHAP with 
aldehyde 1 to give phosphorylated aldol adducts, which were dephosphorylated by acid 
phosphatase (AP) to give aldol product 2, 5, 6.  FruA gave 2 exculsively (dr > 95:5, entry 1), 
FucA provided 5 with 87:13 dr (entry 2), and RhaD yielded 6 with 89:11 dr (entry 3). The 
stereoselectivities of FruA, FucA and RhaD are in consistence with the in vivo results. Therefore, 
these engineered E. coli strains can serve as a general and effective method for the practical 
production of polyhydroxylated molecules. 
 
Table 1.5 One-pot four-enzyme synthesis of 2, 5, 6 
a Determined by 1H NMR. 
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1.6.7 Confirming the E. coli synthetic machinery design by 13C labeling experiment. 
To confirm that C1, C2, C3 three carbons of products were derived from supplemented 
glucose via DHAP of glycolytic pathway, FruA-Y was fed with [U-13C6] glucose as sole carbon 
source and 1 as aldehyde acceptor (Scheme 1.11). Fermentation was carried out in the same 
protocol as described previously by using citric acid-free ECAM as culture medium. After 
purification, product was characterized by 1H, 13C NMR, which indicated that C1, C2, C3 three 
carbons truly came from [U-13C6] glucose as integral of the three carbons are much stronger than 
other carbons due to 100 % 13C abundance.  
 
 
Scheme 1.11 Production of [1,2,3-13C3] 2 by using Glc-13C6 as the sole carbon source. 
 
1.7 Pathway modeling and analysis 
In order to further enhance the production efficiency of current “E. coli synthetic 
machinery”, we tried to develop a mathematical model to analyze the E. coli glycolytic reaction 
networks with the aldol biosynthetic pathway. Through the mathematical model, we can analyze 
the dynamics of the reaction networks, and identify the bottleneck reaction steps/pathways. 
Then, we can explore the parameter space and design space to identify what type of 
modifications in the pathway would result in an increase in final production.  Such a prediction 
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will guide the optimization of E. coli strains (design and construct new E. coli strains based on 
the results of modeling analysis) to improve production efficiency. 
Using optimization-based methods to predict fluxes in metabolic flux balance models has 
been a successful approach for E. coli,91 enabling construction of in silico models,92 inference of 
some regulatory motifs,93 and design of metabolic pathways for optimum performance.94  
The basic principles of Flux Balance Analysis (FBA) models are well established. If it is 
postulated that the cell maximizes a certain metabolic objective, I, then the flux distribution (v) 
can be predicted through solving an optimization problem (Equation 1.1). V is the vector of 
fluxes (v). c is a vector of weights indicating how much each reaction contributes to the objective 
function. cT is the transpose of c. 
 
          
Equation 1.1 
      
At steady state, the changes in the metabolites is zero (Equation 1.2) and the equations 
can be reduce to a set of linear algebraic equations. V is the vector of m fluxes (v) and S is the 
n*m matrix of stoichiometric coefficients of the n metabolites in reactions. 
 
݀ሾܼሿ
݀ݐ ൌ ܵ ∗ ܸ ൌ 0 
Equation 1.2 
 
FBA essentially combine metabolic flux steady state analysis with an assumed/identified 
metabolic objective function. It has been particularly successful in modeling E. coli, by assuming 
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maximum biomass formation in a variety of conditions.95-97 Therefore, we choose to use FBA to 
study the biosynthetic pathway model and develop in silico models of the reaction schemes to 
help understand the biosynthetic systems as well as predict optimal alternatives. 
Central carbon metabolic pathway (containing the phosphotransferase system (PTS), 
glycolysis, pentose-phosphate pathway (PPP)) is the most important among metabolic pathways 
in all microorganisms since it produces energy and precursors for biosynthesis. Therefore, we 
designed a mathematical model consisting of the central carbon metabolic pathway and DHAP-
dependent aldolases mediated biosynthetic pathway. As shown in Scheme 1.12, the constructed 
model consists of 25 metabolites participating in 28 reactions catalyzed by 22 enzymes.  
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Scheme 1.12 Reaction networks of E. coli central carbon metabolism. 
 
The reaction network of constructed model was simplified in term of reaction fluxes (v). 
As shown in Scheme 1.13, the simplified model contains 42 internal fluxes (v1 – v42) and 4 
external fluxes (α, β, γ, δ). 
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Scheme 1.13 Simplified reaction network. 
 
According to the simplified reaction network, the mass balance equations of each 
metabolites were reduce to a set of linear algebraic equations, which were then mathematically 
represented as a stoichiometric matrix S25x46, with each row representing one metabolite and each 
column representing the participation of one particular reaction flux across the mass balance of 
all metabolites (Figure 1.2 A). V is the vector of fluxes and X is the vector of metabolites. At 
steady state, the changes in the metabolites is zero. Therefore, dX/dt = S*XT = 0, and Xss 
(concentration of metabolites at steady state) is the solution of this equation.  Therefore, given 
one set of fluxes V0, the corresponding concentration of metabolites Xss0 can be deduced from 
solving the mass balance equation at steady state. However, the total number of enzyme kinetic 
parameters for the 46 fluxes is 136, and almost one third of them are unknown. Without 
complete enzyme kinetic parameters, we couldn’t solve the mass balance equation. Thus, we 
suspended the mathematical modeling. 
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Figure 1.2 FBA analysis of constructed model. 
 
1.8 Conclusions 
Transforming DHAP-dependent aldolases mediated aldol reactions from flask into cell-
based synthesis addressed several key issues plaguing large scale synthetic utility of DHAP-
dependent aldolases: 1) it solves the problem of DHAP availability by in vivo hijacking DHAP 
from glycolysis pathway of bacterial system, 2) it circumvents purification of recombinant 
aldolases and phosphatase, and 3) it dephosphorylates resultant aldol adducts in vivo, thus 
eliminating the additional step for phosphate removal and achieving in vivo phosphate recycling. 
Operational simplicity, low cost and easy to scale up of fermentation renders such transformation 
holds enormous value in synthesis of biologically relevant polyhydroxylated molecules on an 
industrial scale. 
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Moreover, in the final products, the 3 carbons corresponding to the DHAP structure come 
from biomass, the cheapest, sustainable source. And the fermentation process is fully executed in 
environmental friendly conditions. This is in sharp contrast with the conventional non-green 
chemical or in vitro enzymatic synthesis that either uses toxic organic solvents or expensive 
reaction starting materials from non-sustainable petroleum industry. 
Finally, this approach of hijacking valuable biochemical (DHAP) from metabolic 
pathway (glycolysis) and transforming enzymatic reactions (DHAP-dependent aldolases 
catalyzed aldol reactions) from flasks to E. coli cells may open the flood gate that large number 
of biochemicals in microbial metabolic pathways can be utilized. 
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2 CHAPTER 2 STUDY THE MECHANISM OF CHEMICAL DESIALYLATION IN 
THE LIFE PROCESSES 
 
 
2.1 Introduction 
Sialic acids exist in abundance in glycan chains of glycoproteins and glycolipids on the 
surface of all eukaryotic cells and some prokaryotic cells. Their presence affects the molecular 
properties and structure of glycoconjugates, modifying their functions and interactions with other 
molecules.1, 2 Sialic acid residues on glycoproteins and glycolipids have been recognized as 
critical factors modulating molecular recognitions and signaling inside the cell, between the 
cells, between the cells and the extracellular matrix, and between the cells and exogenous 
pathogens.3, 4 
The sialylation status, referring to the expression levels and linkages of sialic acids on the 
cell surface, is determined by the dynamic balance between sialylation and desialylation 
(removal of sialic acids), which dramatically impacts the status, property and function of cells 
(Figure 2.1). Sialylation is mainly regulated through expression and activity of 
sialyltransferases, enzymes that transfer sialic acid residues onto oligosaccharides and 
glycoconjugates. And most sialyltransferases have been identified, cloned and characterized 
from multiple species.5, 6 On the contrary, there is much limited understanding about the 
regulation of desialylation. The mainstream idea attributes desialylation to the sialidases,7, 8 
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enzymes that catalyze the removal of terminal sialic acid residues from sialosides and 
sialoglycoconjugates. However, mammalian sialidases are very unstable outside the cell and 
their extracellular activities are very low.  Meanwhile, more and more emerging evidences, 
including our own, support the existence of chemical desialylation process in which the 
desialylation is brought by reactive oxygen species (ROS) and reaction nitrogen species (RNS) 
under some pathological conditions. 
 
 
Figure 2.1 Dynamics of Sialylation status—sialylation and desialylation 
 
2.2 Structural diversity and biological functions of sialic acids 
Sialic acids are a diverse family of α-keto acidic monosaccharides widely expressed on 
all cell surfaces of animals (e.g., more than 10 million molecules per human erythrocyte) and to a 
less extent in plants and bacteria. N-acetylneuraminic acid (Neu5Ac), N-glycolylneuraminic acid 
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(Neu5Gc), and deaminoneuraminic acid (KDN) are the most well-known members of the sialic 
acid family (Figure 2.2). In addition to these three basic forms, more than 50 distinct sialic acid 
structures have been identified in nature, arising from acetylation, methylation, lactylation, 
sulfation, and phosphorylation of the C-4, C-5, C-7, C-8, or C-9 hydroxyl groups. Sialic acids 
exist predominantly as terminal monosaccharides linked to galactose (Gal) or N-
acetylgaloctosamine (GalNAc) residues in glycan chains through α-2,3- or α-2,6-linkages. They 
can also form a homopolymer of α-2,8-linked polysialic acid (PSA).9-12 
 
 
Figure 2.2 Three basic forms of naturally occurring sialic acids 
 
Given their remarkable diversity in structure, glycosidic linkage, and underlying glycan 
chains, as well their exposed location, sialic acids play important roles in many physiological and 
pathological processes, including platelet clearance, regulation of the immune response, microbe 
binding that leads to infections, brain development, and the progression and spread of human 
malignancies (Figure 2.3).13, 14 Besides to function as recognition sites, sialic acids also can act 
as biological mask to shield recognition sites. Recently, it also has been reported that sialic acids 
can act as antioxidant to scavenge free radicals and protect DNA.15 
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Figure 2.3 Biological functions of sialic acids. 
 
2.3 Biosynthesis of sialoglycoconjugates 
Neu5Ac and KDN are the precursors of all known mammalian sialic acids. In mammals, 
Neu5Ac and KDN are synthesized in the cytosol. Sialic acid synthase catalyzes aldol 
condensation of ManNAc-6-P or Man-6-P with phosphoenolpyruvate (PEP) to yield Neu5Ac-9-
P and KDN-9-P. Subsequently, the condensation products are dephosphorylated by phosphatase 
to give free Neu5Ac and KDN (Scheme 2.1). The free Neu5Ac and KDN enter the nucleus and 
are activated by CMP-Sia synthase to form CMP-Neu5Ac and CMP-KDN, which then return to 
the cytoplasm, and part of CMP-Neu5Ac is converted to CMP-Neu5Gc by CMP-Neu5Ac 
hydroxylase. Then, CMP-Sias (CMP-Neu5Ac, CMP-KDN and CMP-Neu5Gc) are transported 
Blood cell recycling Immune modulation 
Virus infection Neural development 
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into the lumen of Golgi, and Sias are transferred onto newly synthesized glycoconjugates passing 
through Golgi by sialyltransferases. Finally, if necessary, the nascent sialoglycoconjugate is 
further modified by sialic acid modification enzymes before it is delivered to the cell surface. 
However, some modifications are installed onto CMP-Sias before the transfer of Sias to 
glycoconjugates.  
 
 
Scheme 2.1 Biosynthesis of sialoglycoconjugates. 
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2.4 Desialylation is an essential life process and highly associated with human diseases 
Desialylation is an essential part of sialic acid metabolism. Sialic acids attached to a 
glycoconjugate must eventually be removed at some point in the life cycle of the molecule. 
During recycling of cell-surface molecules, sialoglycoconjugates are desialylated in 
endosomal/lysosomal compartments, and the desialylated glycoconjugates can either be further 
degraded or return to the Golgi to undergo re-sialylation and then be delivered back to the cell 
surface. The released sialic acid in lysosomal is delivered back to the cytoplasm, where it is 
either efficiently reutilized (via CMP-Sia) or degraded. For a long time, Sialyltransferases were 
thought to be mainly responsible for the creation and maintenance of a temporal and spatial 
diversity of sialylated moieties. However, the growing evidence suggests that in mammalian 
cells, at least equally important roles belong to desialylation and abnormal of desialylation is 
highly associated with human diseases.16-18  
 
2.5 Mammalian sialidases 
Sialidases may either initiate the catabolism of sialoglycoconjugates or just cleave their 
sialic acid residues, and thereby regulate cell-surface sialic acid presentation. To date, four types 
of mammalian sialidases have been identified and characterized (Table 2.1), and are classified 
upon their subcellular localization, namely the intra-lysosomal sialidase (NEU1, localized at the 
lysosomal inner membranes), the cytosolic sialidase (NEU2, in cytosol), the plasma membrane-
associated sialidase (NEU3, localized in plasma membranes), and the lysosomal or 
mitochondrial membrane-associated sialidase (NEU4, localized in endoplasmic reticulum 
membranes (ER), lysosomal or mitochondrial membranes).19, 20 However, recent observations 
have revealed that the subcellular localization can vary with particular cell stimuli. NEU1 is 
44 
ubiquitously expressed with the highest expression in kidney, pancreas, skeletal muscle, liver, 
lungs, placenta, and brain. NEU2 is found predominantly in muscle tissues. NEU3 has the 
highest expression in adrenal gland, skeletal muscle, heart, testis, and thymus. NEU4 has the 
highest expression in brain, skeletal muscle, heart, placenta, and liver.21 
 
Table 2.1 General properties of mammalian sialidases. 
 
 
In term of substrate specificity, NEU1 is active primarily against sialylated glycopeptides 
and oligosaccharides with lower activity against gangliosides. NEU2 is active against α-2,3-
sialylated oligosaccharides, glycopeptides, and gangliosides. NEU3 is active mainly towards 
gangliosides. NEU4 is active against all types of sialylated glycoconjugates including 
oligosaccharides, glycoproteins, and gangliosides. With respect to expression levels, NEU1 has 
the highest expression level among the four sialidases, although the expression levels of four 
sialidases are very low. NEU3 and NEU4 are generally expressed at 1/10 to 1/20 of the level of 
NEU1. NEU2 is expressed at extremely low level, only 1/4,000 to 1/10,000 of the level of 
NEU1.22 
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Up-regulation of NEU3 has been detected in prostate,23 colon,24 renal25 and ovarian 
cancers.26 On the other hand, cancer cells and tissues tend to show down-regulation of NEU1 and 
NEU4,19, 27-29 although the molecular mechanisms of such regulations are still unknown. In 
addition, mammalian sialidases couldn’t recognize modified sialic acid residues (O-acetylation, 
methylation, lactylation, sulfation, and phosphorylation),30, 31 which further complicates the 
regulatory mechanism of desialylation. However, ROS- and RNS-mediated chemical 
desialylation could cleave sialic acid residues directly, no matter they are modified or not, which 
provided a new dimension for the regulation of cell surface sialylation status. 
In the past decades, more and more emerging evidences, including our own, support the 
existence of chemical desialylation in the life process. 
 
2.6 Evidences for non-sialidase desialylation in the life process. 
In fact, the first direct evidence for chemical desialylation in the life process comes from 
our lab (Glycobiology, 2005 15, 1094-1101). In 2005, in collaboration with Taniguchi’s lab, we 
discovered that the reactive oxygen species (ROS), generated by a combination of hypoxanthine 
and xanthine oxidase (HX/XO), led to the specific cleavage of Neu5Ac from cell surface sialyl 
lewisx (sLex) without up-regulation of sialidases (Figure 2.4).32  
After the cells were treated by HX/XO, desialylation was observed by flow cytometry 
with a sialic acid-specific lectin (SSA), (Figure 2.5 a). The result showed that HX/XO decrease 
the amount of sialic acid on the cell surface. A concomitant increase of free sialic acid was 
observed by HPLC in the supernatant (Figure 2.5 b). Cleavage of sialic acid by ROS was also 
verified by the degradation of 4-methylumbelliferyl-Neu5Ac (4-MU-Neu5Ac) by HX/XO in the 
presence of hydrogen peroxide and iron ion (Figure 2.5 c). These findings suggested that non-
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reducing terminal sialic acid residues were one of the most susceptible targets for ROS, and 
provided the basis for our further mechanistic study.33 
 
Figure 2.4 ROS reduces the cell adhesion of leukemia cell 
 
 
Figure 2.5 a) Flow cytometric analysis of HX/XO mediated desialylation; b) Sialic acid 
concentration in the supernatant; c) The degradation of 4-methylumbelliferyl-Neu5Ac. 
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Subsequent study was based on the Long–Evans Cinnamon (LEC) rat which is 
developing into hepatitis as the result of abnormal copper accumulation in liver. The findings of 
this study show that copper, hydrogen peroxide, and lipid peroxides accumulate to drastically 
high levels in LEC rat serum. The desialylation of sialylated glycoproteins in the LEC rat serum 
was examined by lectin blot and lectin ELISA. The result showed that sialic acid on the 
conjugates was decreased in acute hepatitis as time went by. Further analysis on glycoform of 
transferrin demonstrated that bi-sialylated and asialo-agalacto biantennary sugar chains existed 
on transferrin in the acute hepatitis rats (Figure 2.6). In addition, treatment of non-hepatitis rat 
serum with copper ions and hydrogen peroxide decreased tri-sialylated sugar chain of the normal 
transferrin and increased bi-sialylated and asialylated biantennary sugar chains. This was the first 
evidence which directly supported the connection between non-sialidase desialylation and ROS 
in vivo, and indicated that non-sialidase desialylation may contribute the development of acute 
hepatitis.34 
 
 
Figure 2.6 The glycoform change in the LEC rat 
 
Recently, a method has been developed by Nakagomi’s lab to detect the existence of 
oxidation product of N-acetylneuraminic acid (Neu5Ac), 4-(acetylamino)-2,4-dideoxy-D-
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glycero-D-galacto-octonic acid (ADOA).35 4-(N, N-dimethylaminosulfonyl)-7-(2-
aminoethylamino)-2,1,3-benzoxadiazole (DBD-ED) with strong fluorescence was utilized to 
label Neu5Ac and ADOA in the serum. The modified Neu5Ac and ADOA were separated by a 
hydrophilic interaction liquid chromatography column (HILIC) and determined by fluorometric 
detection. The results revealed that the concentrations of Neu5Ac and ADOA ranged from 6.30 
M to 25.50 M, and from 0.14 M to 0.49 M in the normal salivary samples, respectively (Figure 
2.7). The heavy smokers who suffer from oxidative stress in their body have much higher 
concentrations of Neu5Ac (17.77- 87.00 M) and ADOA (0.64–3.43 M) than their counterparts in 
saliva. This is the very first time to detect ADOA in biological samples.35 And ADOA could be 
the long-seeking biomarker for non-sialidase desialylation, which could result from desialylation 
during oxidative stress and inflammation.35-37 
 
 
Figure 2.7 HPLC profiles of Neu5Ac-DBD-ED (peak 2) and ADOA-DBD-ED (peak 1) 
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2.7 Synthesis of sialic acid conjugates for the study of chemical desialylation 
For the study of chemical desialylation, a library of sialic acid conjugates (Figure 2.8) 
were synthesized including unnatural Neu5Ac derivatives (7-11), Neu5Ac, Neu5Gc and KDN 
conjugated oligosaccharides (12-20), Neu5Ac conjugated glycopeptide (21) and glycoproteins 
(22, 23). In 7 and 8, Neu5Ac linked to a small methyl group. In 9, a strong electron withdrawing 
group CF3 was introduced. In 10, a bulky adamantanyl group was introduced. In 11, an electron 
donating allyl group was introduced. 7-11 were used to study the electronic and steric effect of 
underlying residue on desialylation (7 vs 9 vs 11, 7 vs 10), as well as the difference between α 
and β linkage (7 vs 8). 12 and 13, 14 and 15, 16 and 17 were used to compare the desialylation of 
Neu5Ac, Neu5Gc and KDN, as well as the difference between α-2, 3- and α-2, 6-linkages. 18, 19 
and 20 were used to compare the desialylation of α-2, 8-linked and α-2, 3- and α-2, 6-linked 
Neu5Ac. 21, 22, 23 were used to study the desialylation of glycopeptide and glycoprotein. 
As shown in Scheme 2.2, 7-11 were chemically synthesized according to the literature.38-
41 12-20 were efficiently synthesized by transferring sialic acid residues onto 1-β-methyl 
lactoside (Lac-β-OMe) through one-pot multi-enzyme strategy.42-44 As shown in Scheme 2.3,   
Neu5Ac was activated to CMP-Neu5Ac by sialic acid synthase (NmCSS), and then transferred 
onto Lac-β-OMe by α-2,3-sialyltransferase (PmsT1) and α-2,6-sialyltransferase (Pd2,6ST) to 
give 12 and 13 respectively. 12 and 13 were further sialylated by an α-2,8-sialyltransferase 
(CstII) to yield 18 and 19. 20 was synthesized by transferring an α-2,6-linked Neu5Ac to 12. 14 
and 15, 16 and 17 were synthesized by transferring Neu5Gc and KDN onto Lac-β-OMe by 
PmsT1 and Pd2,6ST. 21 was isolated from egg yolk.45 22 and 23 were synthesized by coupling 
NHS activated sugar-linker conjugates with BSA (Scheme 2.4). 
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Figure 2.8 Sialic acid conjugates library for the study of chemical desialylation. 
 
 
Scheme 2.2 Chemical synthesis of 7-11. 
51 
 
Scheme 2.3 Enzymatic synthesis of 12-20. 
 
 
Scheme 2.4 Synthesis of 22 and 23. 
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2.8 Chemical desialylation 
Direct oxidative decarboxylation of Neu5Ac to ADOA with H2O2 was reported by 
Tomita lab46 and Yamazaki lab (Scheme 2.5a),47 and the mechanism was proposed to go through 
Baeyer-Villiger rearrangement.47 The cyclic Neu5Ac equilibrates with the open chain form. The 
α-keto of open chain form can be attacked by H2O2, followed by Baeyer-Villiger rearrangement 
and decarboxylation, to yield ADOA (Scheme 2.5c). When α-2,8-linked homodimer of Neu5Ac-
Neu5Ac was treated with H2O2, only Neu5Ac-α-2,8-ADOA was afforded,48 which demonstrated 
that the reducing terminal Neu5Ac could be oxidized by H2O2, but non-reducing terminal 
Neu5Ac couldn’t be oxidized by H2O2 (Scheme 2.5b). The failure to oxidize terminal Neu5Ac 
residue of Neu5Ac-α-2,8-ADOA probably is due to that the formation of open chain form is 
blocked. Therefore, attack of H2O2 to α-carbonyl group was blocked. 
 
 
Scheme 2.5 Oxidation of Neu5Ac and Neu5Ac conjugates by H2O2. 
 
However, C. Neyra et al recently reported that polysialic acid could be depolymerized by 
H2O2 at 70 oC (Scheme 2.6), and they proposed the involvement of hydroxyl radical in the 
depolymerization.49 But, the detailed mechanism of such depolymerization is unknown. 
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Scheme 2.6 Depolymerization of polysialic acid. 
 
ROS/RNS are products of normal cellular metabolism, and play important roles in cell 
signaling.50, 51 But high concentration of ROS/RNS would generate oxidative stress and cause 
damage to DNA/RNA, proteins and lipids.52 ROS/RNS mediated damage to DNA/RNA, proteins 
and lipids are widely studied and well characterized. However, the effects of ROS/RNS to 
carbohydrates, especially sialic acid conjugates, are barely studied.53-58 Previous studies 
indicated that ROS/RNS involved in the desialylation of sialic acid conjugates under 
pathological conditions such as inflammation, cardiovascular diseases, diabetes mellitus, 
Hodgkin's lymphoma, dengue infection and sepsis. However, the detailed chemistry of 
ROS/RNS-mediated desialylation is still unknown. In biological system, the most common 
ROS/RNS species are O2•−, H2O2, OH•, OCl−, •NO, •NO2, and ONOO−. 
Therefore, we carried out some preliminary studies on the reaction of sialic acid 
conjugates with H2O2.  It was reported that normal cells could survive in H2O2 aqueous with the 
concentration of H2O2 up to 240 µM.59  Thus, we treated sialic acid conjugates (12, 13, 21, 22, 
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23) with 200 µM H2O2 at pH 7.4 and rt for 12 h, then analyzed the products with LC-MS/MS. As 
summarized in Table 2.2, all sialic acid conjugates could be desialylated by H2O2 with ADOA as 
the major product and Neu5Ac as the minor product, though the total conversion is low. These 
results suggest that H2O2 can mediate desialylation of cellular sialic acid conjugates under 
oxidative stress. 
 
Table 2.2 H2O2 mediated desialylation. 
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We also performed some preliminary experiments on the reaction of sialic acid 
conjugates with ROS.  all ROS species in biological systems are derived from O2•−,60 and OH•, 
is the most reactive specie of ROS.61-63 Thus, 22 was treated with different ROS generating 
systems including HX/XO (O2•−), HX/XO/Fe2+, H2O2/Fe2+ (OH•) and HX/XO/H2O2/Fe2+ (Table 
2.3). LC–MS/MS analysis showed that these ROS generating systems could directly remove 
terminal Neu5Ac to yield ADOA and Neu5Ac, especially the combination system of 
HX/XO/H2O2/Fe2+. These results suggested that ROS can directly remove terminal sialic acid 
residues of cellular sialic acid conjugates.  
 
Table 2.3 Desialylation of glycoprotein by ROS. 
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Based on these results and previous studies on oxidation of sialic acids, the probable 
mechanism of ROS mediated desialylation was proposed to go through radical decarboxylation. 
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As depicted in scheme 2.7, ROS abstract one electron from carboxylate group of sialic acid 
residue to generate carboxyl radical I, which is highly active and spontaneously decarboxylates 
to give the corresponding alkyl radical II. Due to anomeric effect, II can easily be further 
oxidized to generate oxocarbenium III, which is then attacked by water to give lactone IV. After 
hydrolysis of IV, ADOA was provided. 
 
 
Scheme 2.7 Proposed mechanism of ROS mediated desialylation. 
 
2.9 Mimicking ROS-mediated desialylation by electrochemical oxidation 
Kolbe electrolysis (or Kolbe oxidation) is a standard oxidative decarboxylation reaction, 
as well as a classical radical reaction.64-66 Hofer-Moest reaction is an extension of Kolbe 
oxidation.67-70 Under electrolytic condition, carboxylic acid loses one electron to generate 
carboxyl radical, which is highly active and spontaneously decarboxylates to give the 
corresponding alkyl radical. Then the alkyl radical further loses one electron to generate alkyl 
cation, which reacts with a nucleophile to give decarboxylative coupling product (Scheme 2.8). 
The proposed mechanism of ROS mediated desialylation highly resembles the mechanism of 
Hofer-Moest reaction. Therefore, we used electrochemical oxidation to mimic ROS/RNS 
mediated desialylation.  
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Scheme 2.8 Kolbe oxidation and Hofer-Moest reaction. 
 
Boron doped diamond (BDD) is an excellent electrode material with wide  potential 
window in aqueous solution, low background currents (low capacitance), reduced fouling, non-
corroding at high temperatures, pressures and in challenging environments, and excellent 
biocompatibility, which make it an intriguing material for electroanalysis and electrochemical 
research.71-75 Therefore, we used BBD electrode to mimic the oxidative desialylation of sialic 
acid conjugates.  
12 was dissolved in NaClO4 (0.2 M) aqueous solution and the pH of the solution was 
adjusted to 7.4 by 0.1 M NaOH. Then two BBD electrodes were inserted to the stirred solution 
and 2.8 V voltage was applied at room temperature. During electrolysis, the pH of the solution 
was maintained to 7.4 by adding 0.1 M NaOH. After complete consumption of 12, the reaction 
mixture was concentrated and purified by silica gel flash chromatography, then Bio-Gel P-2 gel 
filtration to give ADOA with 37% yield. 
 
2.9.1 Optimization of electrochemical desialylation 
After validation of such electrochemical mimicry of oxidative desialylation, we set out to 
optimize electrolysis conditions by using 12 as the model substrate. Several key parameters 
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critical to electrolysis were investigated (Table 2.4). Voltage is critical for electrochemical 
oxidation. At high voltage, sialic acid conjugates can be efficiently desialylated. However, the 
product ADOA also can be further oxidized at high voltage, which will make the electrochemical 
desialylation very complex to analyze. In order to determine the optimal voltage, the 
electrochemical desialylation was conducted under a variety of voltages, ranging from 2.0 V to 
2.8 V (entries 1-5). At 2.0 V, no reaction at all. At 2.2 V, 12 could be slowly desialylated and 
ADOA was provided as the major product. At 2.4 V, 12 was efficiently desialylated and ADOA 
was provided with 62% yield. At 2.6 V and 2.8 V, 12 was quickly desialylated, however, the 
yield of ADOA decreased, which may be caused by further oxidization of ADOA or other side-
reactions for oxidation of 12. Therefore, the stability of ADOA under different voltage was 
examined. As shown in Figure 2.9, at 2.4 V, ADOA couldn’t be oxidized at all. At 2.6 V, 
ADOA was slowly oxidized (less than 5 % for 12 h). At 2.8 V, ADOA was substantially 
oxidized. Therefore, the best voltage for electrochemical desialylation of sialic acid conjugates is 
2.4 V.  
NaClO4, KNO3 and NaH2PO4/Na2HPO4 are three common electrolytes used for 
electrolysis in water. Therefore, KNO3 and NaH2PO4/Na2HPO4 were examined. When KNO3 
was used as electrolyte, 12 was desialylated at 2.4 V and ADOA was provided with 54% yield. 
However, the electrolysis time was elongated to 72 h. When NaH2PO4/Na2HPO4 was used as 
electrolyte, 12 was desialylated very slowly (less than 10% in 12 h) at 2.4 V. Therefore, the 
voltage was increased to 2.6 V, and 12 was completely desialylated in 16 h and ADOA was 
provided with 46% yield. Therefore, NaClO4 was chosen as the electrolyte. 
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 Table 2.4 Optimization of electrolysis conditions. 
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Figure 2.9 Stability of ADOA under different voltage. 
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2.9.2 Electrochemical desialylation of sialic acid conjugates 
After identified the optimal conditions, the synthesized sialic acid conjugates in Figure 
2.8 were applied to electrochemical desialylation. In order to study the effect of underlying 
residue on electrochemical desialylation, Ne5Ac and its derivatives were electrolyzed first 
(Table 2.5, entries 1-5). Methyl α-Neu5Ac 7 could be efficiently desialylated at 2.6 V and 
ADOA was generated with 57% yield in 47 h (entry 1). In contrast, the β-anomer 8 couldn’t be 
electrolyzed until the voltage was increased to 3.0 V (entry 2), which indicates that there is a 
huge difference in activity between α- and β-anomers. In 9, a strong electron withdrawing group 
CF3 was introduced, which made 9 easier to be electrolyzed and ADOA was provided with 65% 
yield in 20 h (entry 3). In 10, a bulky 1-adamantyl group was introduced, which made 10 easier 
to be electrolyzed and ADOA was provided with 56% yield in 15 h (entry 4).When free Neu5Ac 
was electrolyzed, the voltage needed to be increased to 2.8 V and ADOA was provided with 47% 
yield (entry 5). In water, free Neu5Ac is an equilibrium mixture of α- and β-anomers, which 
consists of 92.1% β-anomer and 7.5% α-anomer at pH 8.0.76 Since β-anomer is much more 
difficult to be electrolyzed, α-anomer was oxidized and then β-anomer was converted to α-
anomer. Therefore, 2.8 V is the voltage for eletrolysis of α-anomer. 
Then, Neu5Ac conjugated oligosaccharides 12, 13, 18, 19 and 20 were electrolyzed to 
study the effect of sialic acid linkages on desialylation. 12 could be efficiently desialylated at 2.4 
V and ADOA was provided with 62% yield (entry 6). 13 was more difficult to be electrolyzed. 
Therefore, the voltage was increased to 2.6 V and ADOA was provided with 56% yield (entry 7). 
Both 14 and 15 could be efficiently desialylated at 2.6 V and ADOA was provided with 90% 
yield in 32 h (entry 8) and 92% yield in 24 h (entry 9) respectively. 
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Table 2.5 Electrochemical desialylation of sialic acid conjugates. 
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Compared to monosialylated 12 and 13, the activities of disialylated 18, 19 and 20 were 
even lower. Therefore, high voltage and long electrolysis time were employed. For 18, 19 and 
20, ADOA was provided with 45%, 49% and 60% yields respectively (Table 2.6, entries 1-3). 
 
Table 2.6 Electrochemical desialylation of sialic acid conjugates. 
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Since 18, 19 and 20 were desialylated, their desialylation processes were studied in detail. 
As shown in Figure 2.10, 18 can be sequentially desialylated from the terminal, or cleaved at the 
internal α-2,3-linkage directly to give Neu5Ac-ADOA, which can be further oxidized to give two 
ADOA. According to the Mass result, Neu5Ac-ADOA was detected and Neu5Ac-Lac-OMe 
wasn’t detected. Therefore, 18 was desialylated by cleavage at the internal α-2,3-linkage directly, 
which indicated that α-2,3-linked Neu5Ac was easier to be desialylated than α-2,8-linked 
Neu5Ac. 
 
 
Figure 2.10 Electrochemical desialylation of 18. 
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For 19, the two Neu5Ac residues also can be sequentially desialylated from the terminal, 
or cleaved at the internal α-2,6-linkage directly to give Neu5Ac-ADOA (Figure 2.11). 
According to the Mass result, Neu5Ac-Lac-OMe was detected and Neu5Ac-ADOA wasn’t 
detected. Therefore, 18 was sequentially desialylated from the terminal, which indicated that α-
2,8-linked Neu5Ac was easier to be desialylated than α-2,6-linked Neu5Ac. 
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Figure 2.11 Electrochemical desialylation of 19. 
 
65 
According to the desialylation of 18 and 19, the two Neu5Ac residues on 20 can either be 
desialylated at 3 positon first, then 6 position, or be desialylated simultaneously (Scheme 2.9). 
However, the molecular mass of intermediates in both two pathways is same. Therefore, the 
desialylation pathway could be identified by mass spectrometer. Currently, we are trying to use 
CE to determine the desialylation pathway of 20. 
 
 
Scheme 2.9 Electrochemical desialylation of 20. 
 
Neu5Gc conjugated oligosaccharides 14 and 15, KDN conjugated oligosaccharides 16 
and 17, glycopeptide 21, glycoprotein 22 and 23 are still under electrolysis. 
 
2.9.3 Proposed mechanism of electrochemical desialylation 
The mechanism of electrochemical desialylation was proposed to follow the Hofer-Moest 
reaction mechanism. Under electrolytic condition, carboxylate group of sialic acid loses one 
electron to generate carboxyl radical I, which is highly active and spontaneously decarboxylate 
to give the corresponding alkyl radical II (Scheme 2.10a). Due to anomeric effect (Scheme 
2.10b II), II further loses one electron to give oxocarbenium III, which is attacked by water to 
give lactone IV. After hydrolysis of IV, ADOA was provided. The favored electrolytic 
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desialylation of α-linked sialic acid to β-linked sialic acid is due to anomeric effect. When the 
carboxylate group is in axial position (α-linked sialic acid, I), the p orbital of endocyclic oxygen 
is parallel to the σ* orbital of axial C-carboxylate bond; the lone electron pair on p orbital can 
migrate to σ* orbital, therefore, the electron density of carboxylic oxygen is rich, which is easy 
to be oxidized (Scheme 2.10b I).77 Meanwhile, the formed alkyl radical II also can be stabilized 
by this lone electron pair migration (Fig. 7b II). However, when the carboxylate group is in 
equatorial position (β-linked sialic acid), the p orbital and σ* orbital aren’t parallel and this lone 
electron pair migration is blocked. Therefore, it is difficult to be oxidized.78 Introduction of 
bulky group makes the formation of II and III more energy favorable, thus increasing the 
desialylation activity (Table 2.5, entry 4).  
 
 
Scheme 2.10 Proposed mechanism of electrochemical desialylation. 
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2.9.4 Trapping intermediates of electrochemical desialylation 
In order to prove the proposed desialylation mechanism, methyl ester 24 was 
electrolyzed. However, no reaction was detected even though the voltage was increased to 2.8 V 
(Scheme 2.11), which is in sharp contrast to the desialylation of carboxylic acid 7 (Table 2.5, 
entry 1). Thus, the carboxylic acid group on sialic acid residue is essential for the desialylation, 
which is in consistence with our proposed mechanism. 
 
 
Scheme 2.11 Electrochemical desialylation of 24. 
 
Then, we tried to trap intermediates of the proposed desialylation mechanism. 
Intermediate I is highly active and undergoes decarboxylation spontaneously. The lifetime of I is 
extremely short, which makes it difficult to be captured. On the other hand, intermediate II and 
III are relatively stable. Therefore, II and III should be able to be trapped. II can be trapped by 
TEMPO to yield 25,79 or by allyltrimethylsilane to yield 26 (Scheme 2.12a).80-82  III also can be 
captured by some nucleophiles other than water (such as azide, Scheme 2.12b).83 The proposed 
mechanism also can be tested by electrochemical oxidation of 11. According to the proposed 
mechanism, electrochemical decarboxylation of 11 will generate intermediate V, which will 
automatically undergo intramolecular radical cyclization to generate cyclic product 27 (Scheme 
2.12c). Therefore, if cyclic product 27 was detected, that means the proposed mechanism is 
correct. We first tried to capture III with NaN3, but failed. It turned out that azide was reduced 
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under the electrolysis conditions. Currently, we are trying to trap II with TEMPO and 
allyltrimethylsilane, and 11 also is under electrolysis. 
 
 
         Scheme 2.12 Trapping intermediates of electrochemical desialylation. 
 
2.10 Probe chemical desialylation on cellular level 
With the knowledge gained from in vitro chemical desialylation, we plan to briefly 
explore chemical desialylation at cellular level. The main roadblock to evaluate chemical 
desialylation of whole cell is the interference of background and inducible enzymatic 
desialylation of the cells. Apparently, this interference can be suppressed by sialidase inhibitors, 
and many good sialidase inhibitors have been developed including the famous commercial drugs 
Temiflu, Zanamivir and Oseltamivir for influenza infection.84-86 However, these sialidase 
inhibitors are mainly for bacterial sialidases and their inhibitory activities toward mammalian 
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sialidases are quite low.22 In addition, complete inhibition of sialidases also may impact the 
viability and functions of cells. Therefore, using sialidase inhibitors to exclude the interference 
of enzymatic desialylation is not a good choice. Recently, Krishna Kumar et al reported that 
mammalian sialidases couldn’t hydrolyze some N-acyl derivatives of sialic acid, such as N-
pentynoyl sialic acid (Neu5Al).87 Thus, we plan to probe chemical desialylation of cell via 
metabolic glycoengineering. in vivo.88, 89 When the cell is fed with peracetylated N-(4-pentynoyl) 
mannosamine (Ac4ManNAl), Ac4ManNAl will enter the cytoplasm of cells, and be deacetylated 
by esterases. Subsequently, the deacetylated ManNAl will be converted to Neu5Al, which will 
be transferred onto glycoconjugates and eventually present on the cell surface following the 
biosynthetic pathway of sialoglycoconjugates (Figure 2.13). Then, the cell will be treated with 
various ROS/RNS. The released desialylation product will be capture by biotinylated tag via 
click reaction, then enriched via streptavidin column and analyzed by HPLC. Since Neu5Al 
couldn’t be desialylated by sialidases, all captured desialylation products are from the chemical 
desialylation. Therefore, this metabolic glycoengineering approach allows selective detection of 
chemical desialylation on cells, which supports the existence of chemical desialylation in the life 
processes directly. 
 
Figure 2.12 Probe chemical desialylation of cell through metabolic glycoengineering. 
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2.11 Conclusions 
We have successfully used electrochemical oxidation of sialic acid conjugates to mimic 
ROS mediated chemical desialylation. Such electrochemical desialylation mimicry reveals that 
1) β-linked sialic acid is much more difficult to de desialylated than α-linked sialic acid, 2) 
electron withdrawing residue and bulky underlying residue can facilitate the desialylation, 3) α-
2,3-linked sialic acid is easier to be desialylated than α-2,6- and α-2,8-linked sialic acid, which is 
in consistence with the glycosidic linkage preference of NEU190 and NEU2.91 This information 
is highly valuable for identifying the ROS species participated in ROS mediated desialylation 
and unveiling corresponding mechanisms. ROS mediated desialylation was proposed to go 
through radical decarboxylation, and we are trapping intermediates to prove the mechanism. In 
addition, the desialylation product ADOA may become a biomarker for chemical desialylation 
from oxidative stress. 
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3 CHAPTER 3 EXPERIMENTAL PROCEDURES 
3.1 Experiment procedures for transforming DHAP-dependent aldolases mediated aldol 
reaction from flask into cell-based synthesis  
3.1.1 General information 
1H and 13C NMR spectra were recorded on Bruker AV-400 MHz. Chemical shifts are 
expressed in ppm using residual CDCl3 (7.26 ppm for 1H NMR and 77 ppm for 13C NMR) or 
CD3OD (3.31 ppm for 1H NMR and 49 ppm for 13C NMR) or D2O at 298 k as internal standard. 
High-resolution mass spectra were recorded under ESI-TOF Mass spectra conditions. Optical 
rotations were measured with JASCO P-1020 polarimeter. Analytical thin-layer chromatography 
(TLC) was performed on pre-coated plates (Silica Gel 60). Silica gel 60 (E. Merck) was 
employed for all flash chromatography. Reagents and starting materials obtained from 
commercial suppliers were used without further purification unless otherwise noted. 
3.1.2 Bacterial strains and plasmids 
Bacterial strains, plasmids and primers were summarized in Table S1. Pfx DNA 
polymerase was purchased from Invitrogen (CA, USA). Restriction enzymes and T4 ligase were 
purchased from Fermentas (MBI, Canada). Thermus thermophiles HB8 genomic DNA was 
purchased from ATCC (Manassas, VA). Plasmid pKKfda containing fda gene from 
Staphylococcus carnosus TM300 was a kind gift from professor Wolf-Dieter Fessner. Bio gel P-
2 gel and Aminex HPX-87H column (300 × 7.8 mm) were purchased from Bio-Rad 
Laboratories, Inc. (Hercules, CA). XK column (100 × 2.6 cm) was purchased from GE 
Healthcare (Piscataway, NJ). 
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Plasmids, strains and primers used in this study 
Materials  Relevant genotype or primer sequence Source     
Plasmids   
pCDFDuet-1 CloDF13 ori lacI T7lac Strr    Novagen 
pCDF-Y   pCDFDuet-1 harboring yqaB gene from E. coli MG1655 This work 
pCDF-fucA-Y pCDFDuet-1 harboring fucA gene from T. thermophiles HB8 
and yqaB gene from E. coli MG1655 
This work 
pKK-fda   Plasmid pKK223-3 harboring fda gene from S. carnosus Fessner W.D 
et al.(1999)  
pCDF-fda-Y    pCDFDuet-1 harboring fda gene from S. carnosus and yqaB 
gene from E. coli MG1655    
This work 
pCDF-rhuA-Y pCDFDuet-1 harboring rhuA gene from E.coli MG1655 and 
yqaB gene from E.coli MG1655 
This work 
Strains   
DH5α   lacZ∆M15 hsdR recA Gibco-BRL 
MG1655 F- λ- ilvG rfb-50 rph-1 Lab stock 
BL21Star (DE3) F- ompT hsdSB(rB- mB-) gal dcm rne131 (DE3) Invitrogen 
E.coli FucA-Y    BL21Star (DE3) harboring plasmid pCDF-fucA-Y      This work 
E.coli FruA-Y BL21Star (DE3) harboring plasmid pCDF-fda-Y        This work 
E.coli RhuA-Y BL21Star (DE3) harboring plasmid pCDF-rhuA-Y        This work 
   
Primers   
pCDF-Y-F   5'-GCGCCATATGTACGAGCGTTATGCAGGTT-3'(NdeI)      
pCDF-Y-R 5'-TATACTCGAGCAGCAAGCGAACATCCACG-3'(XhoI)    
pCDF-fucA-F     5'-TATAGGATCCGCGCGCCCGGTTGTACG-3'(BamHI)  
pCDF-fucA-R 5'-TATAAAGCTTTCATTCCCCACCCCCCAAG-
3'(HindIII) 
 
pCDF-fda-F       5'-GCGCGGATCCGAACCAAGAACAATT-3'(BamHI)    
pCDF-fda-R 5'-GCGCCTGCAGTTAAGCTTTGTTTACTGAA-3'(PstI)    
pCDF-rhuA-F 5'-GCGTGGATCCGCAAAACATTACTCAGT-3'(BamHI)  
pCDF-rhuA-R 5'-TATAAAGCTTTTACAGCGCCAGCGCACT-3'(HindIII)  
 
3.1.3 Construction of pCDF-fucA-Y, pCDF-fda-Y and pCDF-rhuA-Y plasmids 
Primers pCDF-Y-F and pCDF-Y-R were used to amplify the yqaB gene by PCR using E. 
coli MG1655 genomic DNA as the template. The amplified yqaB gene was digested with NdeI 
and XhoI then inserted into the MCS-2 of pCDFDuet-1 plasmid with the same enzymes digested 
to generate plasmid pCDF-Y. Primers pCDF-fucA-F and pCDF-fucA-R were used to amplify 
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fucA gene encoding T. thermophiles HB8 L-fuculose-1-phosphate aldolase by PCR using T. 
thermophiles HB8 genomic DNA as the template. The amplified fucA gene was digested with 
BamHI and HindIII then ligated into MCS-1 of plasmid pCDF-Y with the same enzymes 
digested to generate plasmid pCDF-fucA-Y. Primers pCDF-fda-F and pCDF-fda-R were used to 
amplify the fda gene encoding fructose-1, 6-bisphosphate aldolase from S.carnosus TM300 by 
PCR with plasmid pkk-fda as the template. The amplified fda was digested by BamHI and PstI 
then inserted into MCS-1 of plasmid pCDF-Y with the same enzymes digested to generate 
plasmid pCDF-fda-Y. Primers pCDF-rhuA-F and pCDF-rhuA-R were used to amplify the gene 
rhuA encoding L-rhamnulose-1-phosphate aldolase with E.coli MG1655 as the template. The 
rhuA gene amplified was digested with BamHI and HindIII then inserted into MCS-1 of plasmid 
pCDF-Y with the same enzymes digested to generate plasmid pCDF-rhuA-Y. These recombinant 
plasmids were all transformed into DH5α strain for amplifying and sequencing. pCDF-fucA-Y, 
pCDF-fda-Y and pCDF-rhuA-Y plasmids were transformed into E.coli strain BL21Star (DE3) 
respectively, resulting in the recombinant strains E.coli FucA-Y, E.coli FruA-Y and E.coli 
RhuA-Y. 
3.1.4 Synthesis of aldehyde acceptors 
3-trifluoroacetamido propanal1, 2 
 
To a stirred solution of 3-aminopropan-1-ol (75 g, 1 mol, 1 equiv), ethyl trifluoroacetate 
(177.5 g, 1.5 mol, 1.25 equiv) was added dropwise at 0 oC. After completion of the addition, the 
mixture was warmed to room temperature and stirred overnight. When 3-aminopropan-1-ol was 
completely consumed, the resulting mixture was evaporated under reduced pressure to afford 3-
trifluoroacetamido propan-1-ol, which was used for the TEMPO oxidation directly. 
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To a stirred solution of 3-trifluoroacetamido propan-1-ol (171 g, 1 mol, 1 equiv) in 
CH2Cl2 (1000 mL), TEMPO (15.6 g, 0.1 mol, 0.1 equiv) was added at 0 oC, followed by 
bis(acetoxy)iodobenzene (BAIB) (354 g, 1.1 mol, 1.1 equiv) in small portions. After the 
addition, the reaction mixture was warmed to room temperature and stirred at rt for 3 days. The 
reaction mixture was extracted with water (200 mL x 3). The aqueous phase was washed with 
hexane, then saturated with NaCl and extracted with CH2Cl2 (500 mL x 3). The organic phase 
was dried over anhydrous Na2SO4 and evaporated under reduced pressure. The residue was 
purified by vacuum distillation to give 3-trifluoroacetamido propanal 87.88 g with 52 % yield. 
1H NMR (400 MHz, CDCl3) δ: 9.82 (s, 1H), 6.91 (s, 1H), 3.65 (dt, J = 6.0, 5.6 Hz, 2H), 2.83 (t, J 
= 5.6 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ: 200.6, 157.3 (q, J = 37.0 Hz), 115.7 (q, J = 286.0 
Hz), 42.5, 33.3; 19F NMR (376 MHz, CDCl3) δ: -76.1 (s, 3F). 
3-trichloroacetamido propanal3 
 
To the cooled (0 °C) solution of 3-aminopropionaldehyde diethylacetal (14.7 g, 100 mmol, 1 
equiv) and TEA (11.13 g, 110 mmol, 1.1 equiv) in CH2Cl2 (150 mL), a solution of 
trichloroacetyl chloride (19.09 g, 105 mmol, 1.05 equiv) in CH2Cl2 (50 mL) was added 
dropwise. After completion of addition, the reaction mixture was allowed to warm to rt and 
stirred overnight. The resulting mixture was washed with water, dried over Na2SO4, and 
concentrated to provide 3-trichloroacetamido propionaldehyde diethylacetal. The crude 3-
trichloroacetamido propionaldehyde diethylacetal was sufficiently pure and was used without 
further purification. 
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The mixture of 3-trichloroacetamido propionaldehyde diethylacetal in 1 M HCl in 
dioxane (100 mL) was stirred at room temperature until completion of the reaction (TLC 
monitored). The resulting reaction mixture was concentrated and the residue was dissolved in 
ethyl acetate, then washed with water, dried over Na2SO4, and concentrated in vacuo to afford 
14.64 g 3-trichloroacetamido propanal with 67 % yield, which was sufficiently pure and was 
used for fermentation without further purification. 1H NMR (400 MHz, CDCl3) δ: 9.82 (s, 1H), 
7.30 (s, 1H), 3.64 (dt, J = 6.0, 6.0 Hz, 2H), 2.84 (t, J = 5.8 Hz, 2H); 13C NMR (100 MHz, CDCl3) 
δ: 200.8, 162.0, 67.0, 42.6, 34.8. 
3-difluoroacetamido propanal  
 
To the cooled (0 °C) solution of 3-aminopropionaldehyde diethylacetal (14.7 g, 100 
mmol, 1 equiv) and TEA (11.13 g, 110 mmol, 1.1 equiv) in CH2Cl2 (150 mL), a solution of 
difluoroacetyl chloride (12.02 g, 105 mmol, 1.05 equiv) in CH2Cl2 (50 mL) was added dropwise. 
After completion of addition, the reaction mixture was allowed to warm to rt and stirred 
overnight. The resulting mixture was washed with water, dried over Na2SO4, and concentrated to 
provide 3-difluoroacetamido propionaldehyde diethylacetal. The crude 3-difluoroacetamido 
propionaldehyde diethylacetal was sufficiently pure and was used without further purification. 
The mixture of 3-difluoroacetamido propionaldehyde diethylacetal in 1 M HCl in 
dioxane (100 mL) was stirred at room temperature until completion of the reaction (TLC 
monitored). The resulting reaction mixture was concentrated and the residue was dissolved in 
ethyl acetate, then washed with water, dried over Na2SO4, and concentrated in vacuo to afford 
9.52 g 3-difluoroacetamido propanal with 63 % yield, which was sufficiently pure and was used 
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for fermentation without further purification. 1H NMR (400 MHz, CDCl3) δ: 9.77 (s, 1H), 7.03 
(s, 1H), 5.85 (t, J = 54 Hz, 1H), 3.62-3.57 (m, 2H), 2.78 (s, 2H); 13C NMR (100 MHz, CDCl3) δ: 
200.7, 162.7 (t, J = 25.3 Hz), 108.2 (t, J = 252.3 Hz), 42.8, 32.7. 
 
(R)-3-trifluoroacetamido-2-hydroxypropanal4 
 
To a stirred solution of (R)-3-aminopropane-1, 2-diol (5 g, 54.95 mmol, 1 equiv) in 
methanol (50 mL), ethyl trifluoroacetate (9.75 g, 68.68 mmol, 1.25 equiv) was added dropwise at 
0 oC. After the addition, the mixture was warmed to room temperature and stirred overnight. 
When (R)-3-aminopropane-1, 2-diol was completely consumed, the resulting mixture was 
evaporated under reduced pressure to afford (R)-3-trifluoroacetamido propan-1, 2-diol 
quantitatively, which was used for the IBX oxidation directly.  
To a stirred solution of (R)-3-trifluoroacetamido propan-1, 2-diol (10.27 g, 54.95 mmol, 1 
equiv) in EtOAc (500 mL), 2-iodoxybenzoic acid (76.3 g, 47 %, 82.5 mmol, 1.5 equiv) was 
added and refluxed overnight. The reaction mixture was quenched by filtering through celite. DD 
water (50 mL) was added to the filtrate and the organic solvent was removed under reduced 
pressure. The pH of the aldehyde solution was adjusted to 5 with NaHCO3. After sterilization by 
filtering through 0.2 μm, nylon, sterile membrane, the resulting aldehyde solution was used for 
fermentation directly. The estimated yield was around 50 %. 
(S)-3-trifluoroacetamido-2-hydroxypropanal 
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The (S)-3-trifluoroacetamido-2-hydroxypropanal was prepared analogously from 
commercial (S)-3-aminopropane-1, 2-diol. The estimated yield was around 50 %. 
3.1.5 Media and fermentation procedures 
20 mL overnight cultured recombinant E.coli strain was inoculated to 1 L LB Broth 
medium (LB broth 25 g/L, NaH2PO4·H2O 10.78 g/L, Na2HPO4·7H2O 17.32 g/L, MgSO4 120.00 
mg/L, ZnSO4 32.30 mg/L, CaCl2 11.10 mg/L, thiamine 10.00 mg/L, streptomycin 50.00 mg/L, 
glucose 4.00 g/L), or ECAM medium (NaH2PO4·H2O 10.78 g/L, Na2HPO4·7H2O 17.32 g/L, KCl 
4.27 g/L, (NH4)2SO4 2.33 g/L, citric acid 1 g/L, MgSO4 1 g/L, CaCl2 40 mg/L, thiamine 10 mg/L, 
EDTA 5 mg/L, FeSO4·7H2O 10 mg/L, ZnSO4·7H2O 2 mg/L, MnSO4·H2O 2 mg/L, CoCl2·6H2O 
0.2 mg/L, CuSO4·5H2O 0.1 mg/L, Na2MoO4·2H2O 0.2 mg/L, H3BO3 0.1 mg/L, streptomycin 
50.00 mg/L, glucose 4.00 g/L) or LB Broth/ECAM (1/1, v/v) medium (LB Broth 12.5 g/L, 
NaH2PO4·H2O 10.78 g/L, Na2HPO4·7H2O 17.32 g/L, KCl 2.14 g/L, (NH4)2SO4 1.17 g/L, citric 
acid 0.5 g/L, MgSO4 0.5 g/L, CaCl2 20 mg/L, thiamine 5 mg/L, EDTA 2.5 mg/L, FeSO4·7H2O 5 
mg/L, ZnSO4·7H2O 1 mg/L, MnSO4·H2O 1 mg/L, CoCl2·6H2O 0.1 mg/L, CuSO4·5H2O 0.05 
mg/L, Na2MoO4·2H2O 0.1 mg/L, H3BO3 0.05 mg/L, streptomycin 50.00 mg/L, glucose 4.00 g/L) 
and grown aerobically at 37 oC, 220 rpm until the OD600 reached 1.80. Then the temperature was 
switched to 30 oC and isopropyl-1-thio-β-D-galactopyranoside (IPTG) was added at a final 
concentration of 1 mM to induce the co-expression of aldolase and phosphatase for 12 h. Then 
aldehyde aqueous solution (sterilized by filtering through 0.2 μm, nylon, sterile membrane) was 
added into the medium with an initial concentration of 20 mM. The consumption of glucose, 
aldehyde and generation of aldol product in the medium were monitored by HPLC (HPX-87H 
Ion Exchange Column, column temperature 60 oC, 5 mM H2SO4, 0.5 mL/min). Aldehyde (totally 
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40 mmol) and glucose were fed when necessary. The fermentation was stopped when the 
concentration of the aldol product reached a plateau. 
When 3-trifluoroacetamido propanal, 3-trichloroacetamido propanal, 3-difluoroacetamido 
propanal, 3-(methylthio)propanal, 4,4,4-trifluorobutanal, (R)-3-trifluoroacetamido-2-
hydroxypropanal and (S)-3-trifluoroacetamido-2-hydroxypropanal were used as the acceptor, LB 
Broth/ECAM (1/1, v/v) medium was used; when D-glyceraldehyde was used as the acceptor, 
ECAM medium was used for easier purification of aldol products. 
3.1.6 Analytical methods 
The progress of the fermentation was monitored by HPLC. Samples were taken at regular 
intervals to monitor the consumption of aldehyedes and generation of aldol products. After 
centrifugation, the supernatant was applied to HPLC column (Aminex HPX-87H, 300 × 7.8 mm) 
with 5 mM sulfuric acid as mobile phase and detected with Refractive Index Detector. The flow 
rate was 0.5 mL/min, and the column temperature was 60 oC. 
 
Standard curve of 2. 
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3.1.7 Product purification 
The fermentation medium was centrifuged to remove E. coli cells and 2 L acetone was 
added to the supernatant to precipitate nucleic acid etc. When 3-trifluoroacetamido propanal, 3-
trichloroacetamido propanal, 3-difluoroacetamido propanal, (R)-3-trifluoroacetamido-2-
hydroxypropanal and (S)-3-trifluoroacetamido-2-hydroxypropanal were used as the acceptor, 
after removal of precipitate, the pH value of resulting supernatant was adjusted to 3 by 
concentrated hydrochloric acid, then silica gel was added and concentrated under reduced 
pressure. The resulting residue was loaded onto a pad of silica gel and washed with 
EtOAc/MeOH/HOAc (20/0.5/0.1, v/v/v). The filtrate was concentrated and the residue was 
purified by C-18 reverse phase silica gel column chromatography (water as the eluent), followed 
by silica gel column chromatography (CH2Cl2/MeOH, 10/1). For (R)-3-trifluoroacetamido-2-
hydroxypropanal and (S)-3-trifluoroacetamido-2-hydroxypropanal, CH2Cl2/MeOH (6/1, v/v) was 
used to wash the residue. The filtrate was concentrated and the resulting residue was purified by 
preparative HPLC (C-18 reverse phase, mobile phase, 5 mM TFA). 
When 3-(methylthio)propanal and 4,4,4-trifluorobutanal were used as the acceptor, after 
removal of precipitate, silica gel was added and the supernatant was concentrated under reduced 
pressure. The resulting residue was loaded onto a pad of silica gel and washed with 
EtOAc/MeOH/HOAc (20/0.5/0.1, v/v/v). The filtrate was concentrated and the residue was 
purified by C-18 reverse phase silica gel column chromatography (water as the eluent), followed 
by silica gel column chromatography (CH2Cl2/MeOH, 15/1). 
When D-glyceraldehyde was used as the acceptor, after removal of precipitate, silica gel 
was added and the supernatant was concentrated under reduced pressure. The resulting residue 
was purified by silica gel column chromatography (EtOAc/iPrOH/H2O 9/3/1 (v/v/v)), followed 
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by Bio gel P-2 column, a mixture of D-psicose and D-sorbose (or D-fructose and glucose) was 
obtained. This mixture was isolated by cation exchange resin column as described below. 
3.1.8 Procedure for isolation of D-sorbose and D-psicose using cation exchange resin (Ca2+ 
form) 
D-Sorbose and D-psicose mixture was dissolved in 3 mL ddH2O and applied to a cation 
exchange resin (Ca2+ form, 100 × 2.6 cm) which was preheated to 65oC using a thermostatic 
jacket. The column was eluted with ddH2O (flow rate ~1.5 mL/min) and the whole isolation 
process was performed at 65-70oC. Fractions were collected with an automatic fraction collector 
and identified by HPLC. D-Sorbose was eluted off first and D-psicose was eluted off in later 
fractions. Fractions containing pure D-sorbose or D-psicose were pooled and lyophilized to give 
pure D-sorbose and D-psicose. Pure D-fructose could also be isolated from glucose according to 
the procedure described above using cation exchange resin. 
3.1.9 Synthesis of D-fagomine, DMJ, DNJ 
 
D-fagomine: 
To a solution of 2 (259 mg, 1 mmol) and K2CO3 (345 mg, 2.5 mmol) in 10 mL water, Pd(OH)2/C 
(10 %) was added. The mixture was hydrogenated (50 psi H2) at room temperature overnight. 
The mixture was filtered through 0.45 µm nylon membrane filter. The filtrate was concentrated 
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and the residue was purified by basic Al2O3 column chromatography 
(THF/MeOH/water/NH4OH) to give 119 mg D-fagomine with 81 % yield.  
DMJ: 
Following the same procedure, 3 (150 mg, 0.55 mmol) was hydrogenated to give 72 mg DMJ 
with 81 % yield. 
DNJ:  
Following the same procedure, 4 (150 mg, 0.55 mmol) was hydrogenated to give 71 mg DNJ 
with 81 % yield. 
3.1.10 One-pot four-enzyme synthesis of 2, 5, 6 
 
To a solution of DL-glycerol 3-phosphate magnesium salt (457.3 mg, 2 mmol) in 10 mL 
ddH2O, aldehyde 1 (253.5 mg, 1.5 mmol) was added at pH 7.0, followed by glycerol phosphate 
oxidase (70 U, 2 mg), catalase (1000 U, 1.2 µL), and aldolase (FruA from Staphylococcus 
carnosus, FucA from Thermus. thermophilus HB8 or RhuA from E. coli, final concentration 0.5 
mg/mL). The mixture was shaken at rt for 22 h and the reaction was monitored by TLC 
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(developed by n-BuOH/AcOH/H2O: 2/1/1 (v/v/v) and stained with anisaldehyde sugar stain). 
The reaction mixture was heated for 10 min at 75 oC, then cooled to rt. Then, pH was adjusted to 
4.7 with 6 M HCl and 11 µL acid phosphatase (18 U) was added and the mixture was shaken 
overnight at 37 oC. After cooling to rt, the pH was adjusted to 7.0 with 1 M NaOH and the 
mixture was diluted with methanol. The solution was filtered through celite and washed with 
methanol. The filtrate was concentrated under reduced pressure and the residue was purified by 
silica gel column chromatography (dichloromethane/methanol: 15/1 (v/v)) to afford product. 
After purification, 137.4 mg 2 was provided with 53 % yield, 124.4 mg 5 was provided with 48 
% yield and 87:13 dr, and 108 mg 6 was provided with 42 % yield and 89:11 dr.  Yields were 
calculated based on L-glycerol 3-phosphate (1 mmol). 
3.1.11 Product characterizations 
(3S, 4R)-6-trifluoroacetamido-1,3,4-trihydroxyhexan-2-one 
1H NMR (400 MHz, CD3OD) δ: 4.54 (d, J = 19.2 Hz, 1H), 4.44 (d, J = 
19.6 Hz, 1H), 4.15 (s, 1H), 3.97 (t, J = 5.6 Hz, 1H), 3.46-3.38 (m, 2H), 
1.85-1.80 (m, 2H); 13C NMR (100 MHz, CD3OD) δ: 213.3, 159.0 (q, J = 36.5 Hz), 117.5 (q, J = 
284.7 Hz), 79.4, 71.1, 67.9, 37.9, 33.3; 19F NMR (376 MHz, CD3OD) δ: -77.4 (s, 3F); HRMS 
(ESI): [M-H]- calcd. for C8H11F3NO5, 258.0595; found, 258.0592. 
(3S, 4R)-6-trichloroacetamido-1,3,4-trihydroxyhexan-2-one 
1H NMR (400 MHz, CD3OD) δ: 4.50 (d, J = 19.2 Hz, 1H), 4.40 (d, J = 
19.2 Hz, 1H), 4.13 (s, 1H), 3.99-3.94 (m, 1H), 3.40 (t, J = 6.8 Hz, 2H), 
1.82 (dt, J = 6.8, 6.8 Hz, 2H); 13C NMR (100 MHz, CD3OD) δ: 213.1, 164.2, 79.3, 71.2, 67.8, 
39.5, 33.2; HRMS (ESI): [M+Na]+ calcd. for C8H12Cl3NNaO5,  329.9673; found, 329.9668. 
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(3S, 4R)-6-difluoroacetamido-1,3,4-trihydroxyhexan-2-one 
1H NMR (400 MHz, CD3OD) δ: 6.00 (t, J = 54.0 Hz, 1H), 4.51 (d, J 
= 19.3 Hz, 1H), 4.41 (d, J = 19.3 Hz, 1H), 4.13 (s, 1H), 3.98-3.93 (m, 
1H), 3.36 (t, J = 6.8 Hz, 2H), 1.73 (dt, J = 6.8, 6.8 Hz, 2H); 13C NMR (100 MHz, CD3OD) δ: 
213.3, 165.1 (t, J = 25.0 Hz), 109.9 (t, J = 240.7 Hz), 79.2, 71.1, 67.7, 37.3, 33.4; HRMS (ESI): 
[M+Na]+ calcd. for C8H13F2NNaO5, 264.0654; found, 264.0648. 
(3S, 4R)-1,3,4-trihydroxy-6-(methylthio)hexan-2-one 
1H NMR (400 MHz, CD3OD) δ: 4.54 (d, J = 19.2 Hz, 1H), 4.44 (d, J = 19.2 
Hz, 1H), 4.14 (d, J = 2 Hz, 1H), 4.07-4.04 (m, 1H), 2.67-2.52 (m, 2H), 2.09 
(s, 3H), 1.88-1.81 (m, 2H); 13C NMR (100 MHz, CD3OD) δ: 213.4, 79.4, 72.2, 67.8, 33.7, 31.3, 
15.3; HRMS (ESI): [M+Na]+ calcd. for C7H14NaO4S, 217.0505; found, 217.0500. 
(3S, 4R)-7,7,7-trifluoro-1,3,4-trihydroxyheptan-2-one  
1H NMR (400 MHz, CD3OD) δ: 4.54 (d, J = 19.6 Hz, 1H), 4.45 (d, J = 
19.6 Hz, 1H), 4.14 (s, 1H), 3.96 (s, 1H), 2.41-2.29 (m, 1H), 2.27-2.16 (m, 
1H), 1.88-1.74 (m, 2H); 13C NMR (100 MHz, CD3OD) δ: 213.2, 128.9 (q, J = 273.4 Hz), 79.3, 
72.0, 67.8, 31.2 (q, J = 28.6 Hz), 26.9; HRMS (ESI): [M-H]- calcd. for C7H10F3O4, 215.0537; 
found, 215.0536. 
D-fructose5 
See reference 5. 
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1H NMR (400 MHz, D2O) δ: 4.12-4.07 (m, 2H), 3.97-3.91 (m, 1H), 3.66-3.61 
(m, 2H), 3.59-3.52 (m, 2H); 13C NMR (100 MHz, D2O) δ: 158.2 (q, J = 37.2 
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Hz), 114.8 (q, J = 284.1 Hz), 100.7, 77.0, 74.7, 74.1, 61.4, 41.0; 19F NMR (376 MHz, CD3OD) 
δ: -75.8 (s, 3F); HRMS (ESI): [M-H]- calcd. for C8H11NO6F3, 274.0540; found, 274.0538. 
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1H NMR (400 MHz, D2O) δ: 4.38-4.21 (m, 2H), 4.09-3.99 (m, 1H), 3.55-3.44 
(m, 3H), 3.43-3.36 (m, 1H); 13C NMR (100 MHz, D2O) δ: 158.1 (q, J = 37.2 
Hz), 114.9 (q, J = 284.1 Hz), 101.0, 74.6, 74.4, 74.0, 61.7, 39.1; 19F NMR (376 MHz, CD3OD) 
δ: -75.8 (s, 3F) ; HRMS (ESI): [M-H]- calcd for C8H11NO6F3, 274.0540; found, 274.0538. 
D-fagomine 
[α]D25 = + 18.6 (c = 0.5 in H2O); 1H NMR (400 MHz, CD3OD) δ: 3.86 (dd, J = 
11.0, 3.0 Hz, 1H), 3.60 (dd, J = 11.0, 6.6 Hz, 1H), 3.40 (ddd, J = 11.2, 8.6, 5.0 Hz, 
1H), 3.10 (t, J = 9.2 Hz, 1H), 3.01 (ddd, J = 12.8, 4.4, 2.4 Hz, 1H), 2.62 (td, J = 12.8, 2.8 Hz, 
1H), 2.47-2.42 (m, 1H), 1.96-1.89 (m, 1H), 1.52-1.42 (m, 1H); 13C NMR (100 MHz, CD3OD) δ: 
75.1, 74.9, 63.2, 63.1, 44.5, 34.6; HRMS (ESI): [M+H]+ calcd. for C6H14NO3, 148.0968; found, 
148.0967. 
1-Deoxynojirimycin (DNJ) 
[α]D25 = + 35.7 (c = 0.3 in H2O); 1H NMR (400 MHz, D2O) δ: 3.85 (dd, J = 
11.6, 3.0 Hz, 1H), 3.68 (dd, J = 11.6, 6.0 Hz, 1H), 3.44 (ddd, J = 10.8, 9.2, 5.2 
Hz, 1H), 3.27 (t, J = 9.0 Hz, 1H), 3.18 (t, J = 9.4 Hz, 1H), 3.07 (dd, J = 12.2, 4.8 Hz, 1H), 2.68 
(ddd, J = 9.6, 6.4, 2.8 Hz, 1H), 2.40 (t, J = 11.6 Hz, 1H),; 13C NMR (100 MHz, D2O) δ: 81.2, 
74.1, 73.5, 64.0, 63.5, 51.4; HRMS (ESI): [M+H]+ calcd. for C6H14NO4, 164.0917; found, 
164.0922. 
1-Deoxymannojirimycin (DMJ) 
NHHO
HO
OH
Fagomine
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[α]D25 = - 38.2 (c = 0.4 in H2O); 1H NMR (400 MHz, D2O) δ: 3.96 (d, J = 1.5 
Hz, 1H), 3.73 (d, J = 4.0 Hz, 2H), 3.56 (dd, J = 19.2, 9.5 Hz, 1H), 3.52 (dd, J 
= 9.5, 2.9 Hz, 1H), 2.97 (dd, J = 14.4, 2.7 Hz, 1H), 2.73 (dd, J = 14.0, 1.2 Hz, 1H), 2.45 (dt, J = 
9.6, 4.0 Hz, 1H); 13C NMR (100 MHz, D2O) δ: 76.6, 71.2, 70.4, 62.8, 62.6, 50.3; HRMS (ESI): 
[M+H]+ calcd. for C6H14NO4, 164.0917; found, 164.0922. 
(3R, 4R)-6-trifluoroacetamido-1,3,4-trihydroxyhexan-2-one  
1H NMR (400 MHz, CD3OD) δ: 4.54 (d, J = 19.6 Hz, 1H), 4.44 (d, J = 
19.2 Hz, 1H), 4.15 (d, J = 1.2 Hz, 1H), 3.97 (t, J = 5.6 Hz, 1H), 3.45-
3.38 (m, 2H), 1.88-1.78 (m, 2H),; 13C NMR (100 MHz, CD3OD) δ: 213.3, 159.0 (q, J = 36.5 
Hz), 117.5 (q, J = 284.7 Hz), 79.4, 71.1, 67.9, 37.9, 33.3; 19F NMR (376 MHz, CD3OD) δ: -77.4 
(s, 3F); HRMS (ESI): [M-H]- calcd. for C8H11F3NO5, 258.0595; found, 258.0592. 
(3R, 4S)-6-trifluoroacetamido-1,3,4-trihydroxyhexan-2-one  
1H NMR (400 MHz, CD3OD) δ: 4.51 (d, J = 19.2 Hz, 1H), 4.41 (d, J = 
19.6 Hz, 1H), 4.12 (s, 1H), 3.94 (t, J = 5.6 Hz, 1H), 3.41-3.36 (m, 2H), 
1.84-1.74 (m, 2H); 13C NMR (100 MHz, CD3OD) δ: 213.3, 159.0 (q, J = 36.5 Hz), 117.5 (q, J = 
284.7 Hz), 79.3, 71.1, 67.8, 37.9, 33.3; 19F NMR (376 MHz, CD3OD) δ: -77.4 (s, 3F); HRMS 
(ESI): [M-H]- calcd. for C8H11F3NO5, 258.0595; found, 258.0592. 
D-psicose6, 7 
See references 6 and 7. 
 
D-sorbose 
See references 6 and 7. 
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[1, 2, 3-13C3] (3S,4R)-6-trifluoroacetamido-1,3,4-trihydroxyhexan-2-one 
1H NMR (400 MHz, CD3OD) δ: 4.75-4.60 (m, 1H), 4.38-4.24 (m, 
1.5H), 4.00-3.95 (m, 1.5H), 3.46-3.39 (m, 2H), 1.84-1.80 (m, 2H); 13C 
NMR (100 MHz, CD3OD) δ: 213.2 (dd, J = 42.7 41.4 Hz), 159.0 (q, J = 36.7 Hz), 117.5 (q, J = 
284.8 Hz), 79.3 (dd, J = 43.1, 12.9 Hz), 71.1 (d, J = 39.6 Hz), 67.8 (dd, J = 40.9, 12.9 Hz), 37.9, 
33.3; HRMS (ESI): [M+Na]+ calcd. for C513C3H12F3NO5, 285.0660; found, 285.0656. 
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3.1.13 NMR spectra 
1H-NMR spectrum of 3-trifluoroacetamido propanal in CDCl3.  
 
13C-NMR spectrum of 3-trifluoroacetamido propanal in CDCl3. 
 
2.
00
2.
04
1.
00
0.
96
2.
82
8
2.
84
2
2.
85
6
3.
62
6
3.
64
0
3.
65
5
3.
66
9
6.
91
1
7.
26
0
9.
81
8
-0
.1
1
33
.3
3
42
.5
3
76
.6
8
77
.0
0
77
.3
2
11
1.
40
11
4.
25
11
7.
11
11
9.
97
15
6.
75
15
7.
12
15
7.
49
15
7.
86
20
0.
56
98 
19F-NMR spectrum of 3-trifluoroacetamido propanal in CDCl3. 
 
1H-NMR spectrum of 3-trichloroacetamido propanal in CDCl3.  
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13C-NMR spectrum of 3-trichloroacetamido propanal in CDCl3. 
 
1H-NMR spectrum of 3-difluoroacetamido propanal in CDCl3.  
 
34
.8
4
42
.5
8
67
.0
0
76
.6
8
77
.0
0
77
.3
2
16
1.
98
20
0.
79
2.
78
0
3.
58
7
3.
59
1
3.
60
0
5.
70
9
5.
84
5
5.
98
0
7.
03
0
7.
26
0
9.
76
7
N
H
CCl3
OO
H
100 
13C-NMR spectrum of 3-difluoroacetamido propanal in CDCl3. 
 
1H-NMR spectrum of (3S, 4R)-6-trifluoroacetamido-1,3,4-trihydroxyhexan-2-one in CD3OD.
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13C-NMR spectrum of (3S, 4R)-6-trifluoroacetamido-1,3,4-trihydroxyhexan-2-one in CD3OD. 
 
19F-NMR spectrum of (3S, 4R)-6-trifluoroacetamido-1,3,4-trihydroxyhexan-2-one in CD3OD.
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1H-NMR spectrum of (3S, 4R)-6-trichloroacetamido-1,3,4-trihydroxyhexan-2-one in CD3OD.  
 
13C-NMR spectrum of (3S, 4R)-6-trichloroacetamido-1,3,4-trihydroxyhexan-2-one in CD3OD. 
 
2.
00
2.
00
0.
99
0.
98
1.
02
1.
02
1.
78
9
1.
80
6
1.
82
4
1.
84
1
3.
31
0
3.
38
1
3.
39
7
3.
41
4
3.
95
0
3.
96
6
3.
97
9
4.
07
3
4.
08
6
4.
13
1
4.
37
9
4.
42
7
4.
47
6
4.
52
4
4.
81
0
33
.2
1
39
.4
9
48
.3
6
48
.5
7
48
.7
9
49
.0
0
49
.2
1
49
.4
3
49
.6
4
49
.8
5
67
.7
7
71
.2
4
79
.3
1
16
4.
19
21
3.
14
HO
OH
O OH
N
H
CCl3
O
HO
OH
O OH
N
H
CCl3
O
103 
1H-NMR spectrum of (3S, 4R)-6-difluoroacetamido-1,3,4-trihydroxyhexan-2-one in CD3OD.  
 
13C-NMR spectrum of (3S, 4R)-6-difluoroacetamido-1,3,4-trihydroxyhexan-2-one in CD3OD. 
 
2.
06
2.
04
0.
95
1.
02
0.
99
1.
00
1.
12
1.
75
3
1.
77
0
1.
78
7
1.
80
3
3.
31
0
3.
34
7
3.
36
3
3.
37
8
3.
94
7
4.
13
1
4.
38
3
4.
43
1
4.
48
4
4.
53
2
4.
75
1
5.
86
8
6.
00
3
6.
13
8
33
.3
8
37
.3
1
48
.3
6
48
.5
7
48
.7
9
49
.0
0
49
.2
1
49
.4
3
49
.6
4
67
.7
4
71
.0
6
79
.2
4
10
7.
47
10
9.
93
11
2.
40
16
4.
87
16
5.
12
16
5.
37
21
3.
30
104 
1H-NMR spectrum of (3S, 4R)-1,3,4-trihydroxy-6-(methylthio)hexan-2-one in CD3OD. 
 
13C-NMR spectrum of (3S, 4R)-1,3,4-trihydroxy-6-(methylthio)hexan-2-one in CD3OD. 
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1H-NMR spectrum of (3S, 4R)-7,7,7-trifluoro-1,3,4-trihydroxyheptan-2-one in CD3OD 
 
13C-NMR spectrum of (3S, 4R)-7,7,7-trifluoro-1,3,4-trihydroxyheptan-2-one in CD3OD 
 
2.
05
1.
05
1.
03
1.
00
1.
02
0.
97
1.
00
1.
76
9
1.
78
2
1.
79
3
1.
80
8
1.
82
4
1.
83
9
1.
85
1
2.
18
3
2.
19
4
2.
20
9
2.
22
1
2.
23
6
2.
24
8
2.
26
3
2.
29
1
2.
30
3
2.
31
9
2.
33
1
2.
34
6
2.
35
7
2.
36
9
3.
31
0
3.
93
8
3.
94
9
3.
95
9
4.
14
2
4.
42
0
4.
46
8
4.
51
7
4.
56
5
4.
83
8
26
.8
6
26
.8
9
30
.7
8
31
.0
7
31
.3
5
31
.6
4
48
.3
6
48
.5
7
48
.7
9
49
.0
0
49
.2
1
49
.4
3
49
.6
4
67
.8
5
71
.9
8
79
.2
7
12
4.
83
12
7.
57
13
0.
30
13
3.
03
21
3.
28
106 
13C-NMR spectrum of (3S, 4R)-7,7,7-trifluoro-1,3,4-trihydroxyheptan-2-one in CD3OD. 
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1H-NMR spectrum of D-fructose standard in D2O 
 
1H-NMR spectrum of D-fructose from fermentation in D2O 
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1H-NMR spectrum of 3 in D2O
 
13C-NMR spectrum of 3 in D2O 
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19F-NMR spectrum of 3 in D2O 
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1H-NMR spectrum of 4 in D2O 
 
13C-NMR spectrum of 4 in D2O 
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19F-NMR spectrum of 4 in D2O 
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1H-NMR spectrum of D-fagomine in CD3OD. 
 
13C-NMR spectrum of D-fagomine in CD3OD. 
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1H-NMR spectrum of 1-Deoxynojirimycin in D2O 
 
13C-NMR spectrum of 1-Deoxynojirimycin in D2O 
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1H-NMR spectrum of 1-Deoxymannojirimycin in D2O 
 
13C-NMR spectrum of 1-Deoxymannojirimycin in D2O 
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1H-NMR spectrum of (3R, 4R)-6-trifluoroacetamido-1,3,4-trihydroxyhexan-2-one in CD3OD.  
 
13C-NMR spectrum of (3R, 4R)-6-trifluoroacetamido-1,3,4-trihydroxyhexan-2-one in CD3OD.  
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19F-NMR spectrum of (3R, 4R)-6-trifluoroacetamido-1,3,4-trihydroxyhexan-2-one in CD3OD.  
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1H-NMR spectrum of (3R, 4S)-6-trifluoroacetamido-1,3,4-trihydroxyhexan-2-one in CD3OD. 
 
13C-NMR spectrum of (3R, 4S)-6-trifluoroacetamido-1,3,4-trihydroxyhexan-2-one in CD3OD.  
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19F-NMR spectrum of (3R, 4S)-6-trifluoroacetamido-1,3,4-trihydroxyhexan-2-one in CD3OD.  
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119 
1H-NMR spectrum of [1, 2, 3-13C3] (3S, 4R)-6-trifluoroacetamido-1,3,4-trihydroxyhexan-2-one in 
CD3OD. 
 
13C-NMR spectrum of [1, 2, 3-13C3] (3S, 4R)-6-trifluoroacetamido-1,3,4-trihydroxyhexan-2-one in 
CD3OD. 
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3.2 Experimental procedures for chemical desialylation 
3.2.1 General information 
All reagents were purchased from commercially sources and were used without further 
purification. Reactions were monitored by thin layer chromatography (TLC) using silica gel 
GF254 plates with detection by short wave UV light (λ = 254 nm) and staining with 10% 
phosphomolybdic acid in EtOH or p–anisaldehyde solution (ethanol/p–anisaldehyde/acetic 
acid/sulfuric acid 135:5:4:1.5), followed by heating on a hot plate. Column chromatography was 
conducted by silica gel (200–300 mesh) with hexane/ethyl acetate/2-propanol and ethyl 
acetate/methanol/water/acetic acid as eluents. 1H NMR and 13C NMR were recorded with Bruker 
AV 400 spectrometer at 400 MHz (1H NMR), 100 MHz (13C NMR) using CDCl3 and D2O as 
solvents. Chemical shifts were reported in δ (ppm) from CDCl3 (7.26 ppm for 1H NMR, 77.00 
ppm for 13C NMR), D2O (4.70 ppm for 1H NMR). Coupling constants were reported in hertz. 
High–resolution mass spectra (HRMS) were obtained on Thermo LTQ-Orbitrap Elite mass 
spectrometer. HPLC of analysis  was performed by  Shimadzu Prominence 20A coupled with 
UV detector at  210 nm and  Aminex HPX-87H column (300 × 7.8 mm)  with 5 mM sulfuric 
acid as mobile phase. The flow rate was 0.5 mL/min. 
3.2.2 Synthesis of sialic acid conjugates 
2-O-Methyl--D-N-acetyl-neuraminic acid 81 
 
 Sialic acid (3.09 g, 10 mmol) was dissolved in anhydrous methanol (200 mL).  
Amberlyst15 hydrogen form ion-exchange resin (6.0 g) was added, and the suspension was 
121 
refluxed at 80 oC for 48 h. TLC analysis showed complete conversion of starting material to a 
major product (ethyl acetate/methanol/water/acetic acid 5:2:1:0.2). The reaction mixture was 
cooled to room temperature and filtered to remove resin. The filtrate was concentrated in vacuum 
to give crude syrup 28, which was then added a mixture of ethyl ether: methanol (3:1, w/w).  The 
solution was kept at 4 oC for 48 h. The solid substance was recovered by filtration and dried on 
oil pump to give 28 (1.75 g, 52%). 
 The  methyl ester 28 (337.3 mg, 1 mmol) was saponified with 0.1 M NaOH (11 mL) 
overnight at room temperature, TLC analysis showed complete conversion of starting material to 
a major product (ethyl acetate/methanol/water/acetic acid 5:2:1:0.2). The solution pH was 
adjusted to pH ~2 with addition of Amberlyst15 hydrogen form ion-exchange resin, and then 
filtered to remove resin. The filtrate was concentrated, passed through a BioGel P-2 Gel filtration 
column and lyophilized to afford 8 as white solid (281.6 mg, 87%). 1H NMR (D2O, 400 MHz): δ 
1.50 (d, J = 12.0 Hz, 1 H), 1.91 (s, 3 H), 2.20 (dd, J = 4.8 Hz, 13.2 Hz, 1 H), 3.06 (s, 3 H), 
3.40(d, J = 9.2 Hz, 1 H), 3.52 (dd, J = 5.6 Hz, 12 Hz, 1 H), 3.64-3.77 (m, 4 H), 3.84-4.88 (m, 1 
H); 13C NMR (D2O, 100 MHz): δ 21.06, 38.71, 49.39, 50.91, 62.45, 65.99, 67.31, 68.91, 69.05, 
99.33, 173.66, 174.30. ESI HRMS: m/z calcd for C12H20NO9 [M-H]- 322.1138, found 322.1127. 
2-O-Methyl--D-N-acetyl-neuraminic acid 7 acid2, 3 
 
A solution of 1-Adamantanyl thiosialoside 29 (1.28 g, 2 mmol) and activated 4Å 
molecular sieves in anhydrous CH2Cl2/CH3CN (2:1, 12 mL) was stirred for 30 min at rt, then 
anhydrous methanol (1 mL) was added. The  reaction mixture was cooled to -78 oC, NIS (1.13 g, 
5 mmol) and TfOH (177 μL, 2 mmol) were added, and stirred at -78 oC for 1 h. TLC analysis 
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showed complete conversion of starting material to a major product (hexane/ethyl acetate/2-
propanol 20:20:1). The reaction was quenched by the addition of 0.2 mL triethylamine and 
filtered. The filtrate was concentrated in vacuum and purified by silica gel chromatography 
(hexane/ethyl acetate/2-propanol, 20:20:1) to afford 30 as a yellow solid (708 mg, 70%).  
Compound 30 (505 mg, 1 mmol) was dissolved in anhydrous methanol (10 mL), catalytic 
amount of sodium methoxide was added to adjust pH to 9. Then the reaction mixture was stirred 
at rt for 2 h. TLC analysis showed complete conversion of starting material to a major product 
(ethyl acetate/methanol/water/acetic acid 5:1:0.5:0.1). The reaction mixture was neutralized with 
Amberlyst15 hydrogen form ion-exchange resin, filtered and concentrated to afford to de-
acetylated compound. Then, 0.1 M NaOH (11 mL) was added and stirred overnight at rt. TLC 
analysis showed complete conversion of starting material to a major product (ethyl 
acetate/methanol/water/acetic acid 5:2:1:0.2). The pH reaction mixture was adjusted 2 with 
Amberlyst15 hydrogen form ion-exchange resin, and then filtered to remove resin. The filtrate 
was concentrated, passed through a BioGel P-2 Gel fitration column and lyophilized to afford 7 
as white solid (293 mg, 91%). 1H NMR (D2O, 400 MHz): δ 1.54 (t, J = 12.0 Hz, 1 H), 1.94 (s, 3 
H), 2.62 (dd, J = 4.4 Hz, 12.4 Hz, 1 H), 3.25 (s, 3 H), 3.50 (d, J = 8.8 Hz, 1 H), 3.52-3.60 (m, 2 
H), 3.62 (d, J = 10.4 Hz, 1 H), 3.70 (d, J = 10.0 Hz, 1 H), 3.76-3.82 (m, 2 H); 13C NMR (D2O, 
100 MHz): δ 21.01, 39.11, 50.55, 50.90, 61.60, 67.17, 70.63, 71.54, 99.64, 172.41, 174.03. ESI 
HRMS: m/z calcd for C12H20NO9 [M-H]- 322.1138, found 322.1127. 
9 
Compound 9 was synthesized by following the same procedure with 2,2,2-trifluoroethanol as 
acceptor. 
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1H NMR (D2O, 400 MHz): δ 1.60 (t, J = 12.0 Hz, 1 H), 1.91 (s, 3 
H), 2.65 (dd, J = 4.4 Hz, 12.4 Hz, 1 H), 3.32 (s, 3 H), 3.45-3.61 (m, 
4 H), 3.69-3.75 (m, 3 H), 3.86-3.94 (m, 1 H), 4.02-4.13 (m, 1 H); 
13C NMR (D2O, 100 MHz): δ 21.03, 38.61, 50.67, 60.43 (q, J = 35 Hz), 61.56, 67.05, 70.50, 
71.78, 99.33, 122.66 (q, J = 275 Hz), 171.51, 174.04. ESI HRMS: m/z calcd for C13H19F3NO9 
[M-H]- 390.1017, found 390.1054. 
10 
Compound 10 was synthesized by following the same procedure with 1-Adamantanol as 
acceptor. 
 1H NMR (D2O, 400 MHz): δ 1.47 (s, 6 H), 1.50 (t, J = 12.0 Hz, 1 H), 
1.83 (s, 6 H), 1.90 (s, 3 H), 1.97 (s, 3 H), 2.60 (dd, J = 4.4 Hz, 12.4 Hz, 
1 H), 3.43-3.48 (m, 2 H), 3.52 (dd, J = 6.0 Hz, 12.4 Hz, 1 H), 3.62-3.66 
(m, 2 H), 3.71-3.76 (m, 2 H); 13C NMR (D2O, 100 MHz): δ 20.95, 
29.82, 34.45, 41.85, 42.79, 50.79, 61.33, 66.94, 67.06, 71.14, 71.90, 78.56, 98.56, 174.01, 
174.51. ESI HRMS: m/z calcd for C21H33NO9 [M-H]- 442.2082, found 442.2063. 
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Neu5Ac--2,3-Lac--OCH3  124, 5 
Lac--OCH3 (10 mM), Neu5Ac (12 mM), cytidine-5’-triphosphate (CTP, 15 mM) and 
MgCl2 (20 mM) were dissolved in  water in a 50 mL centrifuge tube containing Tris-HCl buffer 
(100 mM). An N.meningitidis CMP-sialic acid synthetase NmCSS (0.5 mg) and an -2,3 
sialyltransferase PmST1 (0.2 mg) were added. Water was added to make the final volume of 
reaction mixture to 20 mL (pH, 8.5). The reaction was incubated 3 h at 37 oC with shaking (120 
rpm). TLC analysis showed a major product (ethyl acetate/methanol/water/acetic acid 
5:3:1.5:0.25). The reaction was stopped by adding the same volume of ice-cold ethanol and 
incubating at 4 oC for 30 min. The mixture was centrifuged to remove insoluble materials. The 
supernatant was concentrated by rotary evaporation and purified by Bio-Gel P-2 gel filtration 
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column. The desired product was collected and lyophilized to afford a white solid (107 mg, 
83%). 1H NMR (D2O, 400 MHz): δ 1.78 (t, J = 12.0 Hz, 1 H), 2.02 (s, 3 H), 2.74 (dd, J = 4.8 Hz, 
12.0 Hz, 1 H), 3.29 (t, J = 8.4 Hz, 1 H), 3.56-3.73 (m,14 H), 3.80-3.90 (m, 4 H), 3.94-4.00 (m, 2 
H), 4.10 (dd, J = 2.8 Hz, 10.0 Hz, 1 H), 4.39 (d, J = 8.0 Hz, 1 H), 4.51 (d, J = 8.0 Hz, 1 H). 13C 
NMR (D2O, 100 MHz): δ 21.08, 38.60, 50.68, 56.22, 59.01, 60.01, 61.57, 66.46, 67.07, 67.30, 
68.34, 70.76, 71.78, 71.84, 73.33, 73.73,74.13, 74.44, 77.18, 98.79, 101.62, 102.06, 172.84, 
173.96;ESI HRMS: m/z calcd for C24H40NO19 [M -H]- 646.2195, found 646.2168. 
Neu5Ac--2,6-Lac--OCH3  13 
Lac--OCH3 (10 mM), Neu5Ac (12 mM), CTP (15 mM) and MgCl2 (20 mM) were 
dissolved in water in a 50 mL centrifuge tube containing Tris-HCl buffer (100 mM). NmCSS 
(0.5 mg) and an -2,6 sialyltransferase (Pd2,6ST, 0.2 mg) were added. Water was added to make 
the final volume of reaction mixture to 20 mL (pH, 8.5). The reaction was incubated 3 h at 37 oC 
with shaking (120 rpm). TLC analysis showed a major product (ethyl 
acetate/methanol/water/acetic acid 5:3:1.5:0.25). The reaction was stopped by adding the same 
volume of ice-cold ethanol and incubating at 4 oC for 30 min. The mixture was centrifuged to 
remove insoluble materials. The supernatant was concentrated by rotary evaporation and purified 
by Bio-Gel P-2 gel filtration column. The desired product was collected and lyophilized to afford 
a white solid (105 mg, 81%). 1H NMR (D2O, 400 MHz): δ 1.72 (t, J = 12.0 Hz, 1 H), 2.02 (s, 3 
H), 2.69 (dd, J = 4.4 Hz, 12.4 Hz, 1 H), 3.32 (t, J = 8.0 Hz, 1 H), 3.50-3.72 (m,13 H), 3.88-3.99 
(m, 5 H), 3.92-3.99 (m, 3 H), 4.39-4.42(m, 2 H) 13C NMR (D2O, 100 MHz): δ 21.07, 39.06, 
50.76, 56.14, 59.21, 61.61, 62.52, 67.33, 67.48, 69.76, 70.78, 71.34, 71.49, 71.67, 72.64, 73.60, 
78.62, 99.24, 101.88, 102.21, 172.45, 173.87; ESI HRMS: m/z calcd for C24H40NO19 [M -H]- 
646.2195, found 646.2168. 
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Neu5Gc--2,3-Lac--OCH3  14 
Lac--OCH3 (10 mM), ManNGc (12 mM), sodium pyruvate (60 mM), CTP (15 mM) and 
MgCl2 (20 mM) were dissolved in water in a 50 mL centrifuge tube containing Tris-HCl buffer 
(100 mM). E. coli sialic acid aldolase (0.4 mg), NmCSS (0.5 mg) and PmST1 (0.2 mg) were 
added. Water was added to make the final volume of reaction mixture to 20 mL (pH, 8.5). The 
reaction was incubated 4 h at 37 oC with shaking (120 rpm). TLC analysis showed a major 
product (ethyl acetate/methanol/water/acetic acid 5:3:1.5:0.25). The reaction was stopped by 
adding the same volume of ice-cold ethanol and incubating at 4 oC for 30 min. The mixture was 
centrifuged to remove insoluble materials. The supernatant was concentrated by rotary 
evaporation and purified by Bio-Gel P-2 gel filtration column. The desired product was collected 
and lyophilized to afford a white solid (105 mg, 79%). 
1H NMR (D2O, 400 MHz): δ 1.74 (t, J = 12.0 Hz, 1 H), 2.70 (dd, J = 4.4 Hz, 12.4 Hz, 1 H), 3.23 
(t, J = 8.0 Hz, 1 H), 3.48–3.53 (m, 3 H), 3.50 (s, 3 H), 3.54-3.60 (m, 3 H), 3.61-3.72 (m, 5 H), 
3.72-3.79 (m, 2 H), 3.80-3.87 (m, 2 H), 3.87-3.95 (m, 2 H), 4.02-4.08 (m, 3 H), 4.33 (d, J = 8.0 
Hz, 1 H), 4.45 (d, J = 7.6 Hz, 1 H); 13C NMR (D2O, 100 MHz): δ 39.70, 51.38, 57.21, 60.05, 
60.98, 61.02, 62.54, 67.45, 68.02, 68.09, 69.37, 71.82, 72.60, 72.78, 74.36, 74.77, 75.17, 75.47, 
78.25, 99.81, 102.65, 103.08, 173.91, 175.77; ESI HRMS: m/z calcd for C24H40NO20 [M -H]- 
662.2149, found 662.2103. 
Neu5Gc--2,6-Lac--OCH3  15 
Lac--OCH3 (10 mM), ManNGc (12 mM), sodium pyruvate (60 mM), CTP (15 mM) and 
MgCl2 (20 mM) were dissolved in water in a 50 mL centrifuge tube containing Tris-HCl buffer 
(100 mM). E. coli sialic acid aldolase (0.4 mg), NmCSS (0.5 mg) and Pd2,6ST (0.2 mg) were 
added. Water was added to make the final volume of reaction mixture to 20 mL (pH, 8.5). The 
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reaction was incubated 4 h at 37 oC with shaking (120 rpm). TLC analysis showed a major 
product (ethyl acetate/methanol/water/acetic acid 5:3:1.5:0.25). The reaction was stopped by 
adding the same volume of ice-cold ethanol and incubating at 4 oC for 30 min. The mixture was 
centrifuged to remove insoluble materials. The supernatant was concentrated by rotary 
evaporation and purified by Bio-Gel P-2 gel filtration column. The desired product was collected 
and lyophilized to afford a white solid (106 mg, 80%). 
1H NMR (D2O, 400 MHz): δ 1.67 (t, J = 12.0 Hz, 1 H), 2.64 (dd, J = 4.4 Hz, 12.4 Hz, 1 H), 3.25 
(t, J = 8.4 Hz, 1 H), 3.43-3.60 (m, 8 H), 3.49 (s, 3 H), 3.63-3.71 (m, 3 H), 3.72-3.82 (m, 4 H), 
3.85-3.93 (m, 3 H), 4.03 (s, 2 H), 4.33 (d, J = 7.6 Hz, 1 H), 4.34 (d, J = 7.6 Hz, 1 H); 13C NMR 
(D2O, 100 MHz): δ 40.14, 51.49, 57.15, 59.39, 60.25, 60.99, 62.60, 63.57, 68.07, 68.31, 68.51, 
70.78, 71.83, 72.24, 72.36, 72.68, 73.70, 74.62, 74.64, 79.68, 100.28, 102.90, 103.23, 173.49, 
175.67; ESI HRMS: m/z calcd for C24H40NO20 [M -H]- 662.2149, found 662.2103. 
KDN--2,3-Lac--OCH3  16 
Lac--OCH3 (10 mM), Mannose (12 mM), sodium pyruvate (60 mM), CTP (15 mM) and 
MgCl2 (20 mM) were dissolved in water in a 50 mL centrifuge tube containing Tris-HCl buffer 
(100 mM). E. coli sialic acid aldolase (0.4 mg), NmCSS (0.5 mg) and PmST1 (0.2 mg) were 
added. Water was added to make the final volume of reaction mixture to 20 mL (pH, 8.5). The 
reaction was incubated 4 h at 37 oC with shaking (120 rpm). TLC analysis showed a major 
product (ethyl acetate/methanol/water/acetic acid 5:3:1.5:0.25). The reaction was stopped by 
adding the same volume of ice-cold ethanol and incubating at 4 oC for 30 min. The mixture was 
centrifuged to remove insoluble materials. The supernatant was concentrated by rotary 
evaporation and purified by Bio-Gel P-2 gel filtration column. The desired product was collected 
and lyophilized to afford a white solid (95 mg, 78%). 
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1H NMR (D2O, 400 MHz): δ 1.66 (t, J = 12.0 Hz, 1 H), 2.62 (dd, J = 4.4 Hz, 12.4 Hz, 1 H), 3.22 
(t, J = 8.0 Hz, 1 H), 3.45-3.57 (m, 7 H), 3.49 (s, 3 H), 3.60-3.66 (m, 4 H), 3.72-3.83 (m, 4 H), 
3.87 (s, 1 H), 3.92 (d, J = 12.0 Hz, 1 H), 4.00 (dd, J = 2.4 Hz, 10.0 Hz, 1 H),  4.32 (d, J = 8.0 Hz, 
1 H), 4.43 (d, J = 8.0 Hz, 1 H); 13C NMR (D2O, 100 MHz): δ 38.28, 56.19, 59.03, 60.01, 61.62, 
66.37, 66.70, 68.33, 68.73, 69.23, 71.05, 71.76, 72.89, 73.34, 73.76, 74.17, 74.43, 77.21, 98.76, 
101.64, 102.07, 173.02; ESI HRMS: m/z calcd for C22H37O19 [M -H]- 605.1935, found 605.1906. 
KDN--2,6-Lac--OCH3  17 
Lac--OCH3 (10 mM), Mannose (12 mM), sodium pyruvate (60 mM), CTP (15 mM) and 
MgCl2 (20 mM) were dissolved in water in a 50 mL centrifuge tube containing Tris-HCl buffer 
(100 mM). E. coli sialic acid aldolase (0.4 mg), NmCSS (0.5 mg) and an Pd2,6ST (0.2 mg) were 
added. Water was added to make the final volume of reaction mixture to 20 mL (pH, 8.5). The 
reaction was incubated 7 h at 37 oC with shaking (120 rpm). TLC analysis showed a major 
product (ethyl acetate/methanol/water/acetic acid 5:3:1.5:0.25). The reaction was stopped by 
adding the same volume of ice-cold ethanol and incubating at 4 oC for 30 min. The mixture was 
centrifuged to remove insoluble materials. The supernatant was concentrated by rotary 
evaporation and purified by Bio-Gel P-2 gel filtration column. The desired product was collected 
and lyophilized to afford a white solid (91 mg, 75%). 
1H NMR (D2O, 400 MHz): δ 1.60 (t, J = 12.0 Hz, 1 H), 2.55 (dd, J = 4.4 Hz, 12.4 Hz, 1 H), 3.22 
(t, J = 8.4 Hz, 1 H), 3.42-3.52 (m, 6 H), 3.47 (s, 3 H), 3.53-3.60 (m, 4 H), 3.67-3.74 (m, 3 H), 
3.78-3.83 (m, 3 H), 3.85-3.92 (m, 2 H), 4.30 (d, J = 3.2 Hz, 1 H), 4.32 (d, J = 3.2 Hz, 1 H); 13C 
NMR (D2O, 100 MHz): δ 38.70, 56.14, 59.23, 61.67, 62.57, 67.04, 67.49, 68.84, 69.18, 69.75, 
71.05, 71.33, 71.67, 72.52, 72.72, 73.60, 78.73, 99.24, 101.92, 102.23, 172.68; ESI HRMS: m/z 
calcd for C22H37O19 [M -H]- 605.1935, found 605.1906. 
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Neu5Ac--2,8-Neu5Ac--2,3-Lac--OCH3  186 
 Neu5Ac-α-2,3-Lac-β-OMe  (10 mM), Neu5Ac (12 mM), CTP (15 mM) and MgCl2 (20 
mM) were dissolved in  water in a 50 mL centrifuge tube containing Tris-HCl buffer (100 mM). 
NmCSS (2.5 mg) and Campylobacter jejuni -2,8-sialyltransferase (CstII, 2 mg) were added. 
Water was added to make the final volume of reaction mixture to 10 mL (pH, 8.5). The reaction 
was incubated 20 h at 37 oC with shaking (120 rpm). TLC analysis showed a major product 
(ethyl acetate/methanol/water/acetic acid 5:3:1.5:0.25). The reaction was stopped by adding the 
same volume of ice-cold ethanol and incubating at 4 oC for 30 min. The mixture was centrifuged 
to remove insoluble materials. The supernatant was concentrated by rotary evaporation and 
purified by Bio-Gel P-2 gel filtration column. The desired product was collected and lyophilized 
to afford a white solid (56 mg, 60%). 
1H NMR (D2O, 400 MHz): δ 1.64 (t, J = 12.0 Hz, 2 H), 1.92 (s, 3 H), 1.96 (s, 3 H), 2.57 (dd, J = 
3.8 Hz, 12.2 Hz, 1 H), 2.67 (dd, J = 4.4 Hz, 12.4 Hz, 1 H), 3.20 (t, J = 8.4 Hz, 1 H), 3.45-3.65 
(m, 14 H), 3.47 (s, 3 H), 3.70-3.80 (m, 6 H), 3.84-3.93 (m, 2 H), 3.97-4.09 (m, 3 H), 4.30 (d, J = 
8.0 Hz, 1 H), 4.41 (d, J = 8.0 Hz, 1 H); 13C NMR (D2O, 100 MHz): δ 21.00, 21.28, 38.59, 39.47, 
50.71, 51.22, 56.18, 58.18, 58.94, 60.07, 60.50, 61.53, 66.45, 66.89, 67.09, 67.46, 68.26, 70.72, 
71.63, 71.79, 72.97, 73.27, 73.78, 74.19, 74.43, 76.97, 77.14, 99.17, 99.52, 101.64, 102.07, 
172.30, 172.41, 173.95; ESI HRMS: m/z calcd for C35H57N2O27 [M -H]- 937.3154, found 
937.3111.  
Neu5Ac--2,8-Neu5Ac--2,6-Lac--OCH3  19 
 Neu5Ac-α-2,6-Lac-β-OMe  (10 mM), Neu5Ac (12 mM), CTP (15 mM) and MgCl2 (20 
mM) were dissolved in  water in a 50 mL centrifuge tube containing Tris-HCl buffer (100 mM). 
NmCSS (2.5 mg) and CstII (2 mg) were added. Water was added to make the final volume of 
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reaction mixture to 10 mL (pH, 8.5). The reaction was incubated 20 h at 37 oC with shaking (120 
rpm). TLC analysis showed a major product (ethyl acetate/methanol/water/acetic acid 
5:3:1.5:0.25). The reaction was stopped by adding the same volume of ice-cold ethanol and 
incubating at 4 oC for 30 min. The mixture was centrifuged to remove insoluble materials. The 
supernatant was concentrated by rotary evaporation and purified by Bio-Gel P-2 gel filtration 
column. The desired product was collected and lyophilized to afford a white solid (57 mg, 61%). 
1H NMR (D2O, 400 MHz): δ 1.57 (t, J = 12.0 Hz, 1 H), 1.63 (t, J = 12.0 Hz, 1 H), 1.92 (s, 3 H), 
1.96 (s, 3 H), 2.51 (dd, J = 4.0 Hz, 12.4 Hz, 1 H), 2.67 (dd, J = 4.4 Hz, 12.4 Hz, 1 H), 3.21 (t, J = 
8.4 Hz, 1 H), 3.42-3.58 (m, 12 H), 3.47 (s, 3 H), 3.68-3.74 (m, 6 H), 3.75-3.84 (m, 4 H), 3.88 (d, 
J = 12.4 Hz, 1 H), 4.01 (dd, J = 2.8 Hz, 12.0 Hz, 1 H), 4.09 (s, 1 H), 4.30 (s, 1 H), 4.32 (s, 1 H); 
13C NMR (D2O, 100 MHz): δ 21.01, 21.27, 39.08, 39.47, 50.70, 51.24, 56.11, 59.25, 60.57, 
61.54, 62.77, 66.81, 67.11, 67.47, 68.61, 69.76, 70.70, 71.30, 71.64, 72.72, 73.12, 73.62, 73.65, 
77.52, 78.73, 99.40, 99.90, 101.87, 102.26, 172.29, 172.34, 173.91, 173.94; ESI HRMS: m/z 
calcd for C35H57N2O27 [M -H]- 937.3154, found 937.3111. 
Neu5Ac--2,8-(Neu5Ac--2,3-)Lac--OCH3  20 
 Neu5Ac-α-2,3-Lac--OCH3 (10 mM), Neu5Ac (12 mM), CTP (15 mM) and MgCl2 (20 
mM) were dissolved in water in a 50 mL centrifuge tube containing Tris-HCl buffer (100 mM). 
NmCSS (2.5 mg) and an Pd2,6ST (2 mg) were added. Water was added to make the final volume 
of reaction mixture to 10 mL (pH, 8.5). The reaction was incubated 24 h at 37 oC with shaking 
(120 rpm). TLC analysis showed a major product (ethyl acetate/methanol/water/acetic acid 
5:3:1.5:0.25). The reaction was stopped by adding the same volume of ice-cold ethanol and 
incubating at 4 oC for 30 min. The mixture was centrifuged to remove insoluble materials. The 
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supernatant was concentrated by rotary evaporation and purified by Bio-Gel P-2 gel filtration 
column. The desired product was collected and lyophilized to afford a white solid (69 mg, 74%). 
1H NMR (D2O, 400 MHz): δ 1.62 (t, J = 12.0 Hz, 1 H), 1.68 (t, J = 12.0 Hz, 1 H), 1.90 (s, 6 H), 
2.58 (dd, J = 4.4 Hz, 12.4 Hz, 1 H), 2.62 (dd, J = 4.4 Hz, 12.4 Hz, 1 H), 3.20 (t, J = 8.4 Hz, 1 H), 
3.42-3.60 (m, 13 H), 3.45 (s, 3 H), 3.68-3.78 (m, 8 H), 3.82–3.90 (m, 3 H), 4.00 (dd, J = 2.8 Hz, 
9.6 Hz, 1 H), 4.29 (d, J = 8.0 Hz, 1 H), 4.39 (d, J = 8.0 Hz, 1 H); 13C NMR (D2O, 100 MHz): δ 
21.01, 38.38, 38.95, 50.60, 50.71, 56.10, 59.19, 61.54, 61.60, 62.44, 66.52, 67.03, 67.32, 68.18, 
70.62, 71.46, 71.62, 71.81, 72.41, 73.58, 74.18, 78.62, 98.84, 99.12, 101.87, 101.92, 172.27, 
172.66, 173.81, 173.90; ESI HRMS: m/z calcd for C35H57N2O27 [M -H]- 937.3154, found 
937.3111. 
SGP 21 
SGP was isolated from egg yolk.7 
α-2,3-linked Neu5Ac–BSA 22 and α-2,6-linked Neu5Ac–BSA 23 
 
The NHS activated sugar-linker conjugates were mixed with BSA at a molar ratio of 50:1 
in 3 x PBS buffer (pH 7.4). The solution was incubated overnight at room temperature. Then the 
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resultant solution was ultrafiltered and washed with 1 x PBS buffer using Amicon Centrifugal 
Filter Devices (Ultracel 10, 000). The glycoproteins solution was lyophilized to give a white 
solid. Based on the change of molecular weight between BAS and sugar-BSA conjugates (22, 
23), the loading number of sugars on BSA was calculated. On average, each BSA in 22 contains 
13.8 sugars and each BSA in 23 contains 8.6 sugars. 
 
MALDI-TOF spectra of BSA, 22 and 23. 
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ladder BSA 22 23
 
SDS PAGE of BSA, 22 and 23. 
3.2.3 Synthesis of ADOA, 31, and 32 as analytical standards 
 
ADOA 
 Neu5Ac (309 mg, 1 mmol) was dissolved in 10 mL ddH2O, and the pH of the solution 
was adjusted to 7.5 by 0.1 M NaOH. Then, H2O2 (1.5 eq) was added and the reaction mixture 
was stirred at rt. After complete consumption of Neu5Ac, the reaction mixture was concentrated 
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and purified by Bio-Gel P2 gel filtration column. The desired product was collected and 
lyophilized to afford 265 mg ADOA with 94% yield. 1H NMR (D2O, 400 MHz): δ 1.93 (s, 3 H), 
2.21 (d, J = 6.6 Hz, 2 H), 3.33 (d, J = 9.0 Hz, 1 H), 3.49 (dd, J = 6.4 Hz, J = 12.0 Hz, 1 H), 3.60-
3.64 (m, 1 H), 3.71 (d, J = 12.0 Hz, 1 H), 3.81 (s, 2 H), 4.35 (t, J = 6.8 Hz, 1 H); 13C NMR (D2O, 
100 MHz): δ 20.81, 40.40, 52.45, 62.19, 65.64, 66.65, 68.31, 69.58, 173.37, 178.71. ESI HRMS: 
m/z calcd for C10H18NO8 [M-H]- 280.1111, found 280.1021. 
31 
31 was synthesized by following the same procedure with 87% yield. 1H NMR (D2O, 400 
MHz): δ 2.29 (d, J = 6.0 Hz, 2 H), 3.42 (d, J = 8.8 Hz, 1 H), 3.58 (dd, J = 5.8 Hz, 11.4 Hz, 1 H), 
3.69 (d, J = 11.6 Hz, 1 H), 3.79 (d, J = 12.0 Hz, 1 H), 3.94 (d, J = 10.0 Hz, 1 H), 3.98 (d, J = 
12.0 Hz, 1 H), 4.10 (s, 1 H), 4.47 (t, J = 14.5 Hz, 1 H); 13C NMR (D2O, 100 MHz): 40.64, 52.24, 
59.92, 62.23, 65.80, 66.78, 68.43, 69.71, 174.12; ESI HRMS: m/z calcd for C10H18NO9 [M-H]- 
296.0987, found 296.0931. 
32 
32 was synthesized by following the same procedure with 91% yield. 1H NMR (D2O, 400 
MHz): δ 3.34 (dd, J = 4.8 Hz, 14.8 Hz, 1 H), 3.41 (dd, J = 9.2 Hz, 14.8 Hz, 1 H), 3.44 (d, J = 9.2 
Hz, 1 H), 3.54 (dd, J = 6.0 Hz, 11.6 Hz, 1 H), 3.62-3.71 (m, 2 H), 3.72-3.79 (m, 2 H), 4.18 (t, J = 
6.4 Hz, 1 H); 13C NMR (D2O, 100 MHz): δ 40.58, 62.24, 66.71, 67.45, 68.25, 69.86, 70.38, 
179.29; ESI HRMS: m/z calcd for C8H15O8 [M-H]- 239.0772, found 239.0737. 
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3.2.4 Standard curves of ADOA, 31 and 32 
Standard curve of ADOA 
 
Standard curve of 31 
 
Standard curve of 32 
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3.2.5 Desialylation of sialic acid conjugates by hydrogen peroxide 
12 (8 mM), 13 (8 mM), SGP 21 (4 mM) , 22  (0.06 mM ) and 23  (0.056mM ) were 
treated by H2O2 (2 μL) in 0.1 x PBS buffer (pH 7.4, total volume 100 μL) for 8 h at 37oC, and 
lyophilized to give white solids for analysis. 
The lyophilized samples were dissolved in 200 μL ddH2O, and mix 5 μL of samples with 
5 μL of internal standard (a solution of 13C3-Neu5Ac and 13C3-ADOA). Then 5 μL of the mixture 
was injected to LC-MS/MS system. Neu5Ac, ADOA and IS were separated by a Primesep D 
column (2.1 x 100mm, 5 μm; SIELC Technologies, Prospect Heights, IL, USA). The gradient 
elution time program was used, in which phase A is deionized water containing 10 mM 
ammonium formate and 0.1% formic acid, and phase B is a mixture of 90% acetonitrile, 10% 
water, 3 mM ammonium formate, and 0.04% formic acid. The MS detection was carried out in 
negative electrospray ionization and multiple reactions monitoring (MRM) mode. 
 
3.2.6 Procedure of electrochemical desialylation 
To a stirred solution of sialic acid conjugate (5 mM) and NaClO4 (0.2 M) in 3 mL 
ddH2O, 0.1 M NaOH was added to adjust the pH to 7.5. Then two BBD electrodes were inserted, 
and a direct current power (2.4 - 3.0 V) was applied at rt.  
The progress of the electrochemical desialylation was monitored by HPLC. Samples (15 
µL) were taken at regular intervals to monitor the consumption of sialic acid conjugate and 
generation of ADOA (or 31, 32). The samples were diluted 3 times and then applied to HPLC 
analysis directly (column: Aminex HPX-87H, 300 × 7.8 mm; eluent: 5 mM sulfuric acid 
solution; flow rate: 0.5 mL/min; column temperature 60 oC; detector: UV 210 nm).  
  
137 
3.2.7 References 
1. Veronesi, P.A., Rodriguez, P.E.A., Veronesi, A.M. & Peschechera, E.  80pp. (Therapicon 
S.r.l., Italy . 2011). 
2. Roy, R. & Laferrière, C.A. Synthesis of protein conjugates and analogues of N-
acetylneuraminic acid. Can. J. Chem. 68, 2045-2054 (1990). 
3. Crich, D. & Li, W.J. alpha-selective sialylations at-78 degrees C in nitrile solvents with a 
1-adamantanyl thiosialoside. J. Org. Chem. 72, 7794-7797 (2007). 
4. Yu, H., Huang, S., Chokhawala, H., Sun, M., Zheng, H. & Chen, X. Highly efficient 
chemoenzymatic synthesis of naturally occurring and non-natural alpha-2,6-linked 
sialosides: a P. damsela alpha-2,6-sialyltransferase with extremely flexible donor-
substrate specificity. Angew. Chem., Int. Ed. 45, 3938-3944 (2006). 
5. Chokhawala, H.A., Yu, H. & Chen, X. High-throughput substrate specificity studies of 
sialidases by using chemoenzymatically synthesized sialoside libraries. ChemBioChem 8, 
194-201 (2007). 
6. Yu, H., Lau, K., Thon, V., Autran, C.A., Jantscher-Krenn, E., Xue, M., Li, Y., Sugiarto, 
G., Qu, J., Mu, S., Ding, L., Bode, L. & Chen, X. Synthetic Disialyl Hexasaccharides 
Protect Neonatal Rats from Necrotizing Enterocolitis. Angew. Chem., Int. Ed. 53, 6687-
6691 (2014). 
7. Sun, B., Bao, W., Tian, X., Li, M., Liu, H., Dong, J. & Huang, W. A simplified procedure 
for gram-scale production of sialylglycopeptide (SGP) from egg yolks and subsequent 
semi-synthesis of Man3GlcNAc oxazoline. Carbohydr. Res. 396, 62-69 (2014). 
 
 
  
138 
3.2.9 NMR spectra 
1H-NMR spectrum of ADOA in D2O. 
 
13C-NMR spectrum of ADOA in D2O. 
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13C HSQC-NMR spectrum of ADOA in D2O. 
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1H-NMR spectrum of 31 in D2O.  
 
13C-NMR spectrum of 31 in D2O. 
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13C HSQC-NMR spectrum of 31 in D2O. 
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1H-NMR spectrum of 32 in D2O.  
 
13C-NMR spectrum of 32 in D2O. 
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13C HSQC-NMR spectrum of 32 in D2O. 
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1H-NMR spectrum of 7 in D2O.  
 
13C-NMR spectrum of 7 in D2O. 
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13C HSQC-NMR spectrum of 7 in D2O. 
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1H-NMR spectrum of 8 in D2O.  
 
13C-NMR spectrum of 8 in D2O. 
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13C HSQC-NMR spectrum of 8 in D2O. 
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1H-NMR spectrum of 9 in D2O. 
 
13C-NMR spectrum of 9 in D2O. 
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1H-NMR spectrum of 10 in D2O.  
 
13C-NMR spectrum of 10 in D2O. 
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13C HSQC-NMR spectrum of 10 in D2O. 
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1H-NMR spectrum of 12 in D2O.  
 
13C-NMR spectrum of ADOA in D2O. 
 
152 
13C HSQC-NMR spectrum of 12 in D2O. 
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1H-NMR spectrum of 13 in D2O.  
 
13C-NMR spectrum of 13 in D2O. 
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13C HSQC-NMR spectrum of 13 in D2O. 
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1H-NMR spectrum of 14 in D2O. 
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13C-NMR spectrum of 14 in D2O. 
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13C HSQC-NMR spectrum of 14 in D2O. 
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1H-NMR spectrum of 15 in D2O. 
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13C-NMR spectrum of 15 in D2O. 
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13C HSQC-NMR spectrum of 15 in D2O. 
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1H-NMR spectrum of 16 in D2O.  
 
13C-NMR spectrum of 16 in D2O. 
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13C HSQC-NMR spectrum of 16 in D2O. 
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1H-NMR spectrum of 17 in D2O. 
 
13C-NMR spectrum of 17 in D2O. 
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13C HSQC-NMR spectrum of 17 in D2O. 
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1H-NMR spectrum of 18 in D2O.  
 
13C-NMR spectrum of 18 in D2O. 
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13C HSQC-NMR spectrum of 18 in D2O. 
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1H-NMR spectrum of 19 in D2O.  
 
13C-NMR spectrum of 19 in D2O. 
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13C HSQC-NMR spectrum of 19 in D2O. 
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1H-NMR spectrum of 20 in D2O.  
 
13C-NMR spectrum of 20 in D2O. 
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13C HSQC-NMR spectrum of 20 in D2O. 
 
 
 
 
